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Chapter I. PREFACE 
 
1  Japanese Cedar Pollinosis 
Seasonal allergic rhinitis, also named Japanese cedar (JC) pollinosis, is 
caused by Japanese cedar pollen (JCP). JC pollinosis is a type-I allergic disease 
and is the most common disease in Japan and thus is considered a national 
affliction (Kaneko et al., 2005; Yamada et al., 2014). More than one third of all 
Japanese population have JC pollinosis, and this number has significantly 
increased in the last 2 decades (Okubo et al., 2011; Yamada et al., 2014).  
The main symptoms are sneezing, watery rhinorrhea, nasal blockage and 
itching of eyes which are caused by chemical modulator release such as 
histamine from mast cells and basophils following to the crosslinking of the 
receptors by allergen-IgE binding. In addition, many JC pollinosis patients have 
also been sensitized to cypress pollen scattered after the JCP season by IgE 
cross-reactivity between JCP and cypress (Di Felice et al., 2001), which causes a 
persistent long-term symptom onset.  
 
2  Allergen Specific Immunotherapy 
Allergen specific immunotherapy (AIT) was introduced to treat pollinosis 
or allergic rhinitis more than 100 years ago (Noon, 1911; Freeman, 1911; 
Freeman, 1930). Since then, AIT has been used to treat allergic diseases caused 
by inhalant allergens and is an effective treatment for patients with seasonal or 
perennial allergic rhinoconjunctivitis and asthma. AIT is the practice of 
administering gradually increasing quantities of an allergen extract to an allergic 
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subject (Figure 1) to ameliorate the symptoms associated with the subsequent 
exposure to the causative allergen (Mailling and Weeke, 1993; Bousquet et al., 
1998; Cappella and Durham, 2012; Eifan et al., 2013; Canonica et al., 2014). 
AIT is currently considered to be curative treatment with allergic disease 
although symptomatic treatment such as antihistamines and nasal corticosteroids 
allows tentative relief from symptoms (Bousquet et al., 1998; Canonica et al., 
2014).  
 
 
Figure 1. Gradually increasing quantities of an allergen extract to an 
allergic subject in allergen specific immunotherapy 
 
Subcutaneous immunotherapy (SCIT) has been introduced since 1960’s at 
Japan, and it was used to treat JC pollinosis (Okubo et al., 2011). However, it is 
absolutely disadvantage with a limited usage of SCIT because of severe 
systemic adverse effects such as anaphylaxis (Bernstein et al., 2004) and 
inconveniences such as injection site pain and frequent hospital visits known as 
general drawbacks of SCIT. To solve such adverse effects and inconveniences 
of SCIT, several alternative noninvasive allergen application strategies have 
0
500
1,000
1,500
2,000
2,500
1 3 5 7 9 111315171921232527
Maintenance
phase
Induction
phase
Time
A
lle
rg
en
 e
xt
ra
ct
Chapter I PREFACE 
 3
been investigated, using the oral mucosal, intranasal, bronchial or oral route 
(Valovirta et al., 2004). Only the administration of allergens via the oral 
mucosal route (allergen-specific sublingual immunotherapy: SLIT) gained 
increasing significance as an alternative application strategy to classical 
subcutaneous injections. SLIT is strongly considered to be a safe and efficient 
treatment for respiratory allergy, and has been introduced as an alternative to 
SCIT (Didier et al., 2011; Nelson et al., 2011; Cox et al., 2012; Durham et al., 
2012). In addition, SLIT reduces the burden on patients compared with SCIT 
because it can be administered at home and is associated with fewer severe side 
effects. In clinical use of allergen extract for SLIT, the allergen extract is placed 
under the tongue for 1 or 2 minutes and then swallowed (SLIT-swallow) or spat 
out (SLIT-spit) (Canonica et al., 2014). Currently, SLIT-swallow is performed 
followed the basis of clinical results and pharmacokinetic considerations 
(Canonica and Passalacquea, 2003). 
 
3  Standardized Allergen Extract 
The allergen extract is indispensable for both of diagnosis and treatment 
for allergy disease. The use of standardization of allergen extract is considered 
to be essential to raise reliability in the diagnosis, efficacy and safety in the 
treatment (Reed et al, 1989; Platts-Mills and Chapman, 1991; Ito, 1992) because 
quality of the extract obtained from native materials is affected by various 
reasons. Several position statements were issued from American Academy of 
Allergy and Immunology (1992 and 1993) and American Academy of Allergy, 
Asthma and Immunology (1997) on the recommendation of use of standardized 
extracts for the diagnosis and treatment for allergic diseases. The standardization 
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of allergen extract is the most important to keep their quality as well as 
batch-to-batch control among products from manufacturers. 
In Japan, the Japanese Society of Allergology is the only authority to 
conduct standardization of allergen extract. In fact, allergen extract of JCP 
(henceforth described as JCP-allergen extract) was a first extract standardized by 
the Japanese Society of Allergology in 1995. A standardized JCP-allergen 
extract has been used for SCIT treatment of the JC pollinosis patients from 2000 
(Torii Pharmaceutical Co. Ltd., Pharmaceutical interview form; Standardized 
allergen extract for SCIT [TORII], Japanese Cedar Pollen). The potency of 
JCP-allergen extract is expressed as Japanese allergy units (JAU) as defined by 
the Japanese Society of Allergology based on skin tests of allergy patients. A 
liquid containing 200 or 2,000 JAU/mL is formulated by dilution of the 
standardized JCP-allergen extract original solution (10,000 JAU/mL; Torii 
Pharmaceutical Co. Ltd., Tokyo, Japan) containing the major allergen Cry j 1 
(Yasueda et al., 1983) at 7.3–21.0 μg/mL (Yasueda et al., 1996) to provide the 
indicated potency.   
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4  Sublingual Immunotherapy Droplet of Japanese Cedar Pollen 
Several clinical studies in small patient populations have shown that SLIT 
might be effective for the treatment of patients with JC pollinosis (Horiguchi et 
al., 2008; Okubo et al., 2008; Fujimura et al., 2011). In these clinical 
investigations, SCIT products were used for sublingual administration (SLIT) as 
an alternative route of administration. For the application to SLIT, a modified 
liquid formulation of the SCIT product of standardized allergen extract of JCP 
has been developed (Torii Pharmaceutical Co. Ltd, Tokyo, Japan) (Table 1).  
 
Table 1. Sublingual droplet of Japanese cedar pollen 
Potency of allergen Use in SLIT to JC pollinosis Cry j 1 contents
10,000 JAU/mL Original solution 7.3-21 μg/mL 
2,000 JAU/mL Induction phase Maintenance phase 
Approximately  
3 μg/mL 
200 JAU/mL Induction phase Approximately  0.3 μg/mL 
 
Doses of 200 and 2,000 JAU/mL were used in SLIT. The solution of 200 and 2,000 JAU/mL 
were formulated by dilution using original solution of standardized allergen extract of JCP 
10,000 JAU/mL. A container with a pump to provide 0.2 mL in one push was used in the 
induction phase at doses of 200 and 2,000 JAU/mL. A single usage pouch for the 
maintenance phase was used to deliver 1 mL of 2,000 JAU/mL. 
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5  Nonclinical Study in Drug Development Process  
In drug development, nonclinical studies (pre-clinical studies) are 
essential process before initiating clinical trials for assessment of both safety 
profile and biological activity (Figure 2). The main goal of nonclinical studies is 
to determine the ultimate safety profile of new drug. In fact, different types of 
approach on nonclinical studies are required by authority following a new drug 
application (NDA) process for each drug.  
 
 
Figure 2. Overview of drug development process. 
PD: Pharmacodynamics, PK: Pharmacokinetics 
 
Basic Research
Exploration and screening of the candidate of new drug
Non-clinical Study (Pre-clinical study)
Assessment of  safety and biological activity
(Laboratory and animal studies)
Application for the manufacture and sales approval
Clinical Study
Phase I   ：Determination of safety and dosage (Healthy volunteers) 
Phase II  : Evaluation of effectiveness and side effects (Patient volunteers)
Phase III : Verification of effectiveness and monitor adverse long-term use
(Patient volunteers)
• Pharmacology
• PD and PK
• Toxicology
Approval and Launch
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For instance, the profiles of pharmacology, pharmacodynamics (PD), 
pharmacokinetics (PK) and toxicology are examined in in vitro and in vivo 
studies using animals. These data sets allow estimating a range of safe dose of 
the drug which is suggested to use in clinical trials, mainly Phase I. In Phase II 
of clinical trial, the treatment dose need to be defined either results of Phase I 
study as well as PK/PD data in animals. To guarantee the quality of data in 
nonclinical studies, the toxicological studies for NDA should be conducted 
following Good Laboratory Practices (GLP) compliance according to the test 
system guideline. 
 
In Japan, there is no specific regulatory guideline for AIT drugs in 
Japanese NDA process. Thereby, nonclinical data in AIT products should be 
applied to the regulatory requirements as well as a small molecule of drug. Here, 
nonclinical studies were conducted as a pre-clinical stage for the new drug 
development of SLIT product which is modified liquid formulation of the SCIT 
product. Biological profile and the safety profile of standardized JCP-allergen 
extract were investigated. Furthermore, the concepts of another nonclinical 
study (i.e., pharmacology and ADME) were discussed regarding the current 
position in the new drug development of allergen immunotherapy drug. 
 
(1) Pharmacological profile of JCP-allergen extract 
AIT has been well known as an effective treatment with type-I allergic 
patients as well as only one therapy to acquire to inducing tolerance against 
specific allergen (Jutel et al., 2006; Eifan et al., 2013; Canonica et al., 2014). 
The mechanism of action (tolerance induction) by repeated allergen 
administration is not clear entirely. To investigate mechanism of action on 
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AIT, the disease model using animals is a key to develop a new drug. In the 
reports, a few animal models using sensitization of JCP has been introduced 
and tried to mimic pathophysiology of allergic conditions (Tsunematsu et al., 
2007). However, it is not fully established and validated as a disease model.  
For understanding the efficacy and mechanism of action by the allergen 
extract in AIT, two different aspects of the extracts are existed; antigen 
profile in immunological response and allergen profile in allergenic response 
(Figure 3, refer to introduction of Chapter II). The antigen profile in 
repeated administration is discussed section 4 of Chapter II. For evaluating 
the efficacy in terms of allergen potency, the allergen-IgE binding is a very 
important which is followed by release of chemical modulators such as 
histamine from mast cells. The standardized JCP-allergen extract including 
Cry j 1 and Cry j 2 allergen proteins (Figure 5, introduction of Chapter II) 
known as JCP major allergens (Yasueda et al., 1983; Sakaguchi et al., 1990) 
have a binding potency to specific IgE in sera of JCP-allergic patients 
(Figure 6, refer to introduction of Chapter II). It indicates that 
JCP-allergen extract elicits a total allergic potency. Allergic specific 
response was examined in rat (refer to section 2 in Chapter II).  
 
(2) Pharmacodynamics and Pharmacokinetics (ADME) of JCP-allergen 
extract  
In the process of development of a new drug with small molecule, 
pharmacokinetics in absorption, distribution, metabolism and excretion are 
investigated by in vitro and in vivo assay. Generally, the candidates of drug 
(small molecule) are possible to be traced after dosing in the body using 
labelled candidate. However it is difficult to fully investigate regarding 
ADME on allergen extract because main factors to induce efficacy are 
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proteins which are usually metabolized by enzyme in the body fluids as 
generally known. 
As a characteristic mechanism of SLIT, it is mainly considered to have 
important role in lymph node where is very close to administration site such 
as a mandibular lymph node. Taken this common understanding, the tissue 
concentration and distribution of [125I] Cry j 1 (Cry j 1; major allergen of 
JCP) were examined (Ohashi-Doi et al., 2011). The stability of allergen 
protein in saliva and stomach juice was discussed in section 3 of Chapter 
II.  
 
(3) Toxicology 
The purpose of the toxicological studies conducted here is to estimate 
physical property of JCP-allergen extract to induce any toxic effect by 
repeated dosing. It provides safety profile of JCP-allergen extract. The study 
design is shown in Table 2. 
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Table 2. Study design and implementation on safety evaluation studies 
of JCP-allergen extract  
Study Species of animals 
Number 
of animals Route Test article Dosage 
Repeated dosed toxicity (Chapter III) 
26 weeks 
repeated 
Rats 
(male and 
female) 
12 p.o. 
Saline 0 JAU/kg 
Glycerin solution 0 JAU/kg 
200 JAU solution 
2,000 JAU solution 
10,000 JAU solution 
200 JAU/kg 
2,000 JAU/kg 
10,000 JAU/kg
Local irritation (Chapter IV) 
7 days 
repeated 
Rabbits 
(male) 3 SL 
Saline 0 JAU/site 
Glycerin solution 0 JAU/site 
2,000 JAU solution 400 JAU/site 
14 days 
repeated 
Rats 
(male) 3 p.o. 
Glycerin solution 0 JAU/site 
10,000 JAU 
solution 
250 JAU/site 
1,250 JAU/site
6,250 JAU/site
Genotoxicity (Chapter V) 
Ames test - - - 
Distilled water 0 JAU/plate 
Glycerin solution 0 JAU/plate 
10,000 JAU 
solution 
31.25–1,000 
JAU/plate 
Chromosomal 
aberration test - - - 
Distilled water 0 JAU/mL 
10,000 JAU 
solution 
625–2,500 
JAU/mL 
In vivo 
micronucleus 
test 
Rats 
(male) 5 s.c. 
Distilled water 0 JAU/kg 
Glycerin solution 0 JAU/kg 
10,000 JAU 
solution 
12,500 JAU/kg
25,000 JAU/kg
50,000 JAU/kg
SL: Sublingual 
200 JAU solution: Standardized JCP-allergen extract with allergen potency of 200 JAU/mL 
2,000 JAU solution: Standardized JCP-allergen extract with allergen potency of 2,000 JAU/mL 
10,000 JAU solution: Standardized JCP-allergen extract with allergen potency of 10,000 JAU/mL 
 
Treatment groups are compared with vehicle control group (0 JAU/plate and 0 JAU/kg). Vehicle group (0 
JAU/plate and 0 JAU/kg) are compared with control group; distilled water for Ames test, chromosomal 
aberration test and in vivo micronucleus test; saline for repeated toxicology and local irritation.  
JAU, Japanese allergy units; s.c., sub-cutaneous; p.o., per oral; PBS, phosphate buffered saline.  
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6  Construction of This Article 
In Chapter II, biological profile of standardized JCP-allergen extract is 
focused based on different two aspects of antigen profile and allergen profile. 
JCP-allergen extract possess both potency of antigen profile and allergen profile, 
and it is related to the mechanism of immunotherapy of JCP-allergen extract and 
also itself is causative material for JC pollinosis. In Chapter III, safety 
evaluation on systemic toxicity of repeated dosing is focused. Repeated 26-week 
oral toxicity study in rats was conducted to evaluate the effect of daily long time 
treatment of standardized JCP-allergen extract intended to be used for daily 
treatment by sublingual administration for several years. In Chapter IV, local 
irritation is focused on oral mucosa as first contact site and gastrointestinal (GI) 
tract mucosa as second contact site with consideration of route of SLIT product. 
In Chapter V, safety evaluation on genotoxicity of standardized JCP-allergen 
extract is focused by in vitro and in vivo genotoxicity studies. At last, conclusion 
and prospective in this article is mentioned in Chapter VI. 
Chapter II. BIOLOGICAL PROFILE 
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Chapter II. BIOLOGICAL PROFILE OF 
ALLERGEN EXTRACT OF JAPANESE 
CEDAR POLLEN 
 
1  Introduction 
It has already demonstrated that AIT has been shown to be clinically 
effective in patients with allergic rhinitis and/or asthma. The mechanism of 
allergen immunotherapy is not fully clear, but it is potentially considered that 
modulation of immuno-response involved in induction of T cells, B cells and T 
regulatory (Treg) cells specially (Figure 3).  
In conventional SLIT, generally high-dose allergen should to be treated 
due to initiating immune deviation of Th2 responses in favor of a Th0/Th1 
response and in the generation of IL-10– and TGF-β–producing CD4+CD25+ T 
cells, possibly Treg cells (Robinson et al, 2004; Novak, 2011; Eifan et al, 2013). 
In addition, it is founded that induction of increased Treg cells in the nasal 
mucosa (Radulovic et al., 2008) and sublingual mucosa (Scadding et al, 2010) 
after AIT, strongly suggesting a potential role for Treg cells in the induction of 
allergen-specific tolerance in human. 
It has also considered that antibody response is a key role in 
immuno-modulation during AIT (Figure 4) (Akdis and Akdis, 2011). In fact, 
production allergen-specific IgE and IgG has been investigated in many clinical 
trials. It was reported that a significant increase in serum-specific IgG4 and IgA 
was founded after AIT with grass pollen (Francis et al., 2008; Blaiss et al., 2011), 
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which were associated with an increase in local and/or systemic IL-10 and 
TGF-β (Nouri-Aria et al., 2004; Pilette et al., 2007; Meiler et al, 2008). 
 
Figure 3. Immunological mechanism of allergen specific immunotherapy. 
APC: Allergen-presenting cells; Ag: Antigen, IFN-γ: Interferon gamma; TGF-β: 
Transforming growth factor-beta: Th: T-helper cell; T-reg: T-regulatory cell. 
Inflammatory cell indicates mast cell, basophil and neutrophil. 
Orange arrows represent immune response pathway to natural exposure (low-dose Ag and 
IgE) ; green arrows represent immune response pathway to immunotherapy (high-dose Ag); 
blue blocked lines represent inhibition (high-dose Ag). 
Allergen profile: Allergic response induced by IgE-antigen binding followed by degranulation 
of histamine or other chemical modulator. 
Antigen profile: Immunological response by production of immunoglobulin such as IgG, IgA. 
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Currently, serum levels of allergen-specific IgE and IgG is nominated as 
candidate biomarkers, although there is considerable debate as to whether these 
parameters are related to clinical efficacy. In contrast to SCIT, SLIT appears to 
elicit mucosal IgA responses, which may contribute significantly to tolerance 
induction (Anthony, 2008).  
 
Figure 4. Immunological changes in allergen-specific immunotherapy. 
(Modified from Akdis and Akdis, 2011) 
s-IgE: specific-IgE, s-IgG4: specific-IgG4 
A part of concept on immunological changes in allergen-specific immunotherapy is indicated 
although there is significant variation between subjects and protocols. An early increase and a 
very late decrease in specific IgE level are observed. In particular, the IgG4 level shows a 
relatively early increase that is dose dependent. In some studies allergen-specific 
allergen-specific IgG1 and IgA levels also increase. A significant decrease in the 
allergen-specific IgE/IgG4 ratio occurs after several months. A significant decrease in type I 
skin test reactivity is also observed relatively late in the course of immunotherapy. These 
effects are partially demonstrated in SLIT and are rather weak compared with those seen in 
SCIT.  
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SLIT has a better safety profile compared with SCIT. This is possibly 
because oral antigen-presenting cells (APC; mostly Langerhans and myeloid 
dendritic cells) exhibit a tolerogenic phenotype, despite constant exposure to 
danger signals from food and microbes. This reduces the induction of 
pro-inflammatory immune responses leading to systemic allergic reactions 
(Calderon et al., 2012). Oral tissues contain relatively few mast cells and 
eosinophils, in comparison with subcutaneous tissue, are less likely to give rise 
to anaphylactic reactions. 
 
For AIT products, the allergen or/and protein profile should be evaluated 
due to guarantee induction of immuno-response in the human body. In the case 
of JCP-allergen extract, major allergen, Cry j 1 and Cry 2 were identified, 
confirming allergen/protein profile in standardized JCP-allergen extract (Figure 
5). 
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Figure 5. SDS-PAGE of standardized JCP-allergen extract (2,000 JAU/mL) 
JCP-allergen extract was assessed by SDS-PAGE analysis using a Mini-Protean TGX Precast 
Gel (4-20% gradient, BIO-RAD) under non-reduction conditions followed by staining with 
silver. 
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In addition, the IgE binding activity is recognized as a part of allergic 
activity because it is known that biding between specific IgE and allergen 
triggers to induce allergenic reaction. Therefore, it was demonstrated to having 
potency to binding to specific IgE in sera of JCP sensitized patients with dose 
dependent manner (Figure 6).  
 
 
Figure 6. Total allergic potency of JCP-allergen extract to sera IgE of 
JCP allergic patients.  
Binding potency to specific IgE in sera of JCP-allergic patients was evaluated by ELISA 
system. Diluted JCP-allergen extract was incubated with pooled sera from JCP-allergic 
patients volunteers. The specific IgE binding was detected by anti-human IgE antibody. 
Values are expressed as fluorescence intensity (excitation 360 nm/emission 460 nm). 
 
To investigate on PK (i.e., ADME), the tissue concentration and 
distribution of [125I] Cry j 1 (Cry j 1; major allergen of JCP) were examined in 
rats following sublingual or subcutaneous dosing (Ohashi-Doi et al., 2011). As a 
characteristic mechanism of SLIT, it is demonstrated lower radioactivity in 
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SLIT-rat sera than SCIT-rat, relative high radio activity in mandibular lymph 
node located near administrated site (Figure 7) suggesting involved in the local 
action by SLIT. 
 
In Chapter II, immunological and biological character of JCP-allergen 
extract is focused; allergen profile by induction of specific allergenic response 
(PCA) in rat, biological stability of major allergens in saliva and gastric juice, 
immunological response by repeated administration.  
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A) Radioactivity concentration in tissue  
 
 
B) Whole Body Radioautography 
 
Figure 7. Radioactivity at 2h after sublingual administration of [125I]Cry j 1 
After sublingual administration of [125I]-Cry j 1 at a dose of 7.5 μg/animal (male 
Sprague-Dawley (SD) rats, 7 weeks old), the animals were sacrificed at specified at 2 h (n=3).  
The designated tissues were collected, and the radioactivity concentrations were measured by 
the gamma counter (A). Separate group of naïve rats administered by [125I]-Cry j 1 were used 
(n=1). The rats were euthanized with CO2 inhalation at 2 h after single administration. 
Animals were occluded by 4% carboxymethylcellulose-Na solution, and then body was 
frozen in a dry ice-acetone mixture and 30 mm-thickness sections were prepared by the 
cryomicrotome. The sections were covered with a protective membrane and placed in imaging 
plates (TYPE BAS RS2040, Fujifilm, Japan). The imaging plates were analyzed by a 
Bioimaging analyser (B).  
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2  Allergic Response in Rat Passive Cutaneous Anaphylaxis Reaction 
2.1  Introduction 
PCA, passive cutaneous anaphylaxis reaction, is typical reaction of 
immediate hypersensitivity. Sensitized animal is developed by intradermal 
administration of immunoglobulin and induced cutaneous anaphylaxis reaction 
by antigen administration. In this study, rats were sensitized with mice sera 
obtained by immunization of JCP-allergen extract, followed by injection of 
JCP-allergen extract with trypan-blue. The induced blueing reaction is indication 
of degranulation of histamine or other chemical modulator induced in the 
allergic response. 
All procedures employed in the experiments were approved by the Animal 
Ethics Committee of Nihon Bioresearch Center, Gifu, Japan, in accordance with 
laboratory animal welfare guidelines. 
 
2.2  Materials and Methods 
Two male Crl:CD (Sprague-Dawley) rats were used (9 weeks old, Charles 
River, Kanagawa, Japan). Serial dilutions of mouse anti-JCP-allergen extract 
sera were intradermally injected into shaved dorsal skin. The PCA reaction was 
measured after a 48-h sensitization period followed by intravenous 
administration of 10 mg (protein content) standardized JCP-allergen extract 
original solution (10,000 JAU/mL) in 1 mL/kg of 0.5% Evans blue. After 30 
min, the diameter of blueing reaction in the dorsal skin area was expressed as a 
mean value (mm) of the major and minor diameters in two animals. The PCA 
titer was expressed by the reciprocal of the final dilution giving a positive (> 5 
mm) blueing reaction.  
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2.3  Results and Discussion  
The allergen profile of JCP-allergen extract was confirmed by measuring 
immune responses in animals. Levels of the JCP specific-antibody in serum was 
significantly increased following intraperitoneal (i.p.) administration with alum 
compared with naïve serum in mice and rats (Figure 8).  
A) Mouse serum 
 
B) Rat serum  
 
Figure 8. Induction of immunoglobulin in mice and rats by 
immunization of JCP-allergen extract. 
BALB/C AnNCrlCrLj male mice (A) and BN/CrlCrlj male rats (B) were administered 
intraperitoneally JCP-allergen extract with alum at 0, 1, 2, 3 weeks. Serum was analysed for 
antigen-specific titer by ELISA with indicated dilution ratio.   
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Next, allergic specific reactions were evaluated by PCA in rats (Figure 9) 
using mice sera obtained by JCP-immunization (Figure 8). PCA titer was 
determined to be 128. 
 
 
Figure 9. PCA reaction by JCP-allergen extract in rats.  
Rats were injected intradermally with serial dilutions of mouse anti-JCP allergen extract 
serum. After 48 h, PCA reactions were elicited by intravenous injection of JCP-allergen 
extract. Values are expressed as mean ± SD of 4 sites in two animals. 
 
 
2.4  Short Summary 
The immune reactions induced by JCP-allergen extract were confirmed by 
PCA reaction in sensitized-model rats.  
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3  Biological stability of Major Allergens in Saliva and Gastric Juice 
3.1  Introduction 
In SLIT to allergic patients, the allergen extract is placed under the tongue 
for 1 or 2 minutes and then swallowed (SLIT-swallow) (Canonica and 
Passalacqua, 2003; Canonica et al., 2014). The protein activity profile of major 
allergens in body fluids was not reported.  
In this section, to estimate the protein activity of JCP-allergen extract after 
sublingual administration, biological stability of two major allergens of JCP 
(Cry j 1 and Cry j 2) was analysed by the treatment in human saliva and artificial 
gastric juice in vitro with consideration of SLIT-swallow administration route.  
 
3.2  Materials and Methods 
The extract was prepared from JCP with identification of including of 
major allergens. Saliva was pooled from three volunteers in Torii 
Pharmaceutical Co. Ltd. Artificial gastric juice was prepared by 0.03 mol/L 
NaCl, 0.084 mol/L HCl and 0.32% (w/v) pepsin with adjustment to pH 1.2.  
JCP-allergen extract containing 15 μg/mL Cry j 1 was incubated with 
saliva or artificial gastric juice in 1 mL tube for 2, 15, 30, 1h, 2h and 4h at 37°C 
(n=3). The samples at each point were evaluated Cry j 1 and Cry j 2 contents by 
Enzyme-Linked Immunosorbent Assay (ELISA), total allergic potency by 
binding to specific IgE in sera of JC pollinosis patients and molecular 
based-protein profile by SDS-PAGE (data not shown).  
Cry j 1 and Cry j 2 contents were measured by sandwich ELISA using 
anti-Cry j 1 antibody as stabilized antibody and biotin-anti-Cry j 1 antibody as 
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detection antibody. After peroxidase enzyme reaction, Absorbance 490 nm was 
detected and concentrations of Cry j 1 or Cry j 2 were calculated.  
Total allergenic potency was detected by inhibition ELISA system. Pooled 
sera from JCP-allergic patient volunteers (Torii Pharmaceutical Co. Ltd.) were 
used. Coated JCP-allergen extract was incubated with the pooled sera 
pre-treated with each test samples. Anti-human IgE antibody labelled with 
-D-galactosidase reacts to JCP-allergen extract-binding IgE in the well of the 
microplate. Fluorescence was measured by plate reader. Control value is 
obtained by pretreatment with buffer. The % inhibition was against control 
value.  
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3.3  Results and Discussion  
Cry j 1 and Cry j 2 contents by ELISA (antigen-antibody reaction) and 
total allergic potency (binding to specific antibody in JC pollinosis patients) 
were measured after treatment in saliva and artificial gastric juice.  
In saliva, Cry j 1 and Cry 2 were stable for 2, 15 and 30 min treatment. 
The content of Cry j 1 was not affected by saliva in 1 h, 2 h and 4 h as maximum 
treatment time. The content of Cry j 2 was slowly decreased from 30 min to 4 h 
at less than 40% of initiation. Total allergic potency was not changed by 
treatment with saliva (Figure 10). On the other hand, in artificial gastric juice,  
Cry j 1 was disappeared immediately and Cry j 2 was detected approximately 
70 % at 0 min followed by decrease to 0% at 15 min and longer time. Total 
allergic potency was decreased immediately after addition of JCP-allergen 
extract into artificial gastric juice (Figure 11). The result by SDS-PAGE was 
consistent with ELISA and total allergic potency (data not shown).  
Regarding another allergen, house dust mite, Der f 1 and Der f 2 were 
investigated on the activity after treatment with body fluids (Du et al., 2011). 
For the results mention above, it is suggested that major allergens of 
JCP-allergen extract could be stable in saliva at sublingual administration in 
human (2 min). The major allergens are considered to be degraded immediately 
after the swallowing, and lost allergic potency in gastric juice of a stomach.  
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A) Saliva (human) 
 
 
B) Gastric juice (artificial) 
 
 
Figure 10. Major allergen contents after treatment with human saliva 
and artificial gastric juice. 
JCP-allergen extract was treated with human saliva (A) and artificial gastric juice (B) for 0, 2, 
15, 30, 1 h, 2 h and 4 h at 37°C (n=3). Each sample was evaluated Cry j 1 and Cry j 2 
concentrations by Cry j 1 specific sandwich ELISA and Cry j 2 specific sandwich ELISA, 
respectively. The % of control was calculated as the % ratio of Cry j 1 or Cry j 2 
concentration compared to control (before treatment).Values are expressed as mean ± SD of 
tree experiments.  
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A) Saliva (human) 
 
 
B) Gastric juice (artificial) 
 
Figure 11. Total allergic potency after treatment with human saliva and 
artificial gastric juice. 
JCP-allergen extract was treated with human saliva (A) and artificial gastric juice (B) for 0, 2, 
15, 30, 1 h, 2 h and 4 h at 37°C (n=3). Each sample was evaluated total allergic potency by 
inhibition ELISA. The sera of JCP-allergic patients were pre-treated with the each sample and 
JCP-allergen extract specific IgE binding was detected as fluorescence. The inhibition % was 
calculated as the % ratio of fluorescence intensity compared to control (sera pre-treated with 
buffer).Values are expressed as mean ± SD of tree experiments.   
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3.4  Short Summary 
It is suggested that major allergens of JCP-allergen extract could be stable 
in saliva at sublingual administration (2 min). The major allergens are 
considered to be degraded immediately after the swallowing, and lost allergic 
potency in gastric juice of a stomach. 
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4  Immunological Response in Rat induced by Repeated Administration 
4.1  Introduction 
Allergen extract have two sides of immunological properties; antigen 
profile and allergy profile. The antigen profile is characterized with the potency 
to change the induction of immunoglobulin. As mentioned in introduction of 
Chapter II, the changes on immunoglobulin-based immunological reaction (IgG 
subtype, IgE, and IgA in SLIT) and cell-based immune response induced by 
repeated administration of allergen extract are key events in mechanism of AIT. 
Allergen exposure modifies serum levels of allergen-specific IgE and IgG in 
AIT, shown in Figure 4 in introduction. 
To evaluate antigen profile of JCP-allergen extract, I established ELISA test 
method for detection of specific IgG to Cry j 1 in sera (Figure 12). In this 
section, specific IgG to Cry j 1 was measured by the established ELISA method 
following 26 weeks repeated administration. Two different routes as oral 
administration and subcutaneous administration were compared.   
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Figure 12. Detection of Cry j 1 specific IgE by ELISA 
Allergen-specific IgG in rat sera was detected by ELISA system. Cry j 1 specific IgG binds to 
immobilized Cry j 1 followed by being detected with HRP-conjugate 2nd antibody. Enzyme 
reaction is used for the final detection.  
 
 
The serum samples were obtained from 26 weeks repeated toxicological 
studies by oral and subcutaneous administration studies under GLP compliance, 
and measurement was conducted separately under non-GLP compliance.  
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4.2  Materials and Methods 
The sera samples of rats (n=12) in blood chemistry of 26 weeks repeated 
toxicological studies were used for analyze of immune response to JCP-allergen 
extract. The measurement of Cry j 1-specific IgG was conducted in separate 
study of 26 weeks repeated toxicological studies by oral administration (refer to 
Chapter III; 200, 2,000, 10,000 JAU/kg) and subcutaneous injection (2,000, 
10,000 JAU/kg). These sera were obtained at one day after last dosing at 26 
weeks. 
Cry j 1-specific IgG in sera were detected by ELISA as below. Microtitre 
plates (Thermo Fisher Scientific, Inc., Waltham, MA) were coated with 10 
μg/mL of Cry j 1 (Torii Pharmaceutical Co. Ltd.) in 100 μL of PBS buffer 
overnight at 4°C. The plates were washed three times with Tris buffered saline 
containing 0.05% Tween 20 (T-TBS) and incubated with blocking buffer for 2 h 
at 25°C. The blocking buffer is PBS containing 5 mg/mL BSA, 1.0 w/v% Block 
Ace and 0.05 vol% Tween 20. After washing three times, rat sera were added to 
the wells and incubated for 2 h at 25°C. The anti-Cry j 1 IgG (Asahi Food & 
Healthcare, Ltd., Tokyo, Japan) was used as positive control. Negative control 
was sera of normal rats used in 8-fold dilution. After washing three times, 
HRT-ProteinG was added to the wells for 1 h at 25°C. After washing three times, 
TMB solution was added and enzyme reaction was stopped with 1 mol/L H2SO4 
after 15 min incubation. The absorbance at 450 nm (A450) was measured by 
micro plate reader GENios (TECAN Austria GmbH, Grödig, Austria).  
`Positive` was defined as more than 2-fold A450 of negative control in this 
study in preliminary study based on statistical analysis (Shankar et al., 2008). 
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4.3  Results and Discussion  
In the rat sera with repeated oral administration, no apparent increase was 
shown compared to negative control (normal sera; A450 = 0.064) and no 
dose-dependent change was observed in 200, 2,000 and 10,000 JAU/kg of male 
and female as shown in Figure 13 A (median; 0.058, 0.057, 0.056 respectively in 
male and 0.058, 0.055, 0.056 respectively in female). Only one male and female 
in 10,000 JAU/mL showed slight increase and defined as positive.  
In the rat sera with repeated subcutaneous injection, all the male and 
female sample showed higher values than negative control (normal sera; A450 = 
0.064). The median values were higher in 10,000 JAU/mL (0.220 in male, 0.207 
in female) than 2,000 JAU/mL (0.165 in male, 0.134 in female) as shown in 
Figure 13 B. The 10 male and 7 female in at 2,000 JAU/kg, 9 male and 9 female 
at 10,000 JAU/kg were showed positive on Cry j 1-specific IgG production after 
26 weeks repeated dosing of JCP-allergen extract.  
On the other hand, Cry j 1 concentration in sera was measured in 26 
weeks repeated treatment at 0, 13 and 26 weeks at 1, 2, 4, 8, 24 hr after dosing 
for each time points (data not shown). In oral administration, there was no 
detection of Cry j 1 after 0, 13 and 26 weeks administration. In subcutaneous 
injection, Cry j 1 was not detected in 0, 13 weeks and detected in only one 
female after 26 weeks administration at 1 h (1.52 ng/mL) and 2 h (1.01 ng/mL) 
time points after administration.    
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A) Oral administration 
 
 
B) Subcutaneous administration 
 
 
Figure 13. Cry j 1-specific IgG in rat sera following 26 weeks repeated 
administration of JCP-allergen extract. 
Rats were administered 200, 2,000 or 10,000 JAU/kg of JCP-allergen extract daily for 26 
weeks orally (A) or 2,000 or 10,000 JAU/kg daily for 26 weeks subcutaneously (B). Samples 
were collected at one day after last dosing at 26 weeks. The dots are individual values of 12 
animals per group. The bars indicate median values in each group.  
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4.4  Short Summary 
There is a difference on the potency to induce specific IgG between oral 
and subcutaneous treatment of JCP-allergen extract in rats. The 26 weeks 
repeated subcutaneous injection of JCP-allergen extract increased Cry j 1 
specific IgG in rat sera, although except for one female, Cry j 1 in sera was not 
detected when during 26 weeks. Oral administration showed no increase in Cry j 
1 specific IgG with consistent to no Cry j 1 detection in sera during 26 weeks.  
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5  Summary 
Two types of profile of antigen and allergen were investigated with 
JCP-allergen extract.  
The immune reactions induced by JCP-allergen extract were confirmed by 
PCA reaction in sensitized-model rats. It is suggested that major allergens of 
JCP-allergen extract are stable in saliva at sublingual administration (2 min), and 
degraded and lost allergic potency immediately after swallowing in gastric juice 
of a stomach. 
There is a difference on the potency to induce specific IgG between oral 
and subcutaneous treatment in rats. Subcutaneous injection relatively increased 
Cry j 1 specific IgG in sera of rats treated 26 weeks repeated dosing, although 
Cry j 1 in sera was not detected in the study. Oral administration showed no 
increase in Cry j 1 specific IgG with no Cry j 1 in sera during 26 weeks. 
 
As mentioned above, allergen extract have antigen profile and allergen 
profile, and it is a key points on use of allergen extract for specific 
immunotherapy. 
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Chapter III. SAFETY EVALUATION ON 
SYSTEMIC TOXICITY OF REPEATED 
DOSED RATS WITH ALLERGEN 
EXTRACT OF JAPANESE CEDAR 
POLLEN  
 
1  Introduction 
In the process of the research and development of new drug which is 
treated long period with repeated administration in human, systemic toxicity of 
repeated dosed animals is needed to be evaluated in nonclinical study before 
initiation of clinical trial in long period. The purpose of repeated toxicity study 
using animals is to examine the potential of the drug to induce toxic changes 
when repeated administration in long period, providing the dose which induce 
toxic changes, type and grade of toxicity, No-observed-adverse-effect level 
(NOAEL) which is the maximal dose indicating no toxicity and 
No-observed-effect level (NOEL) which is maximal dose indicating no effect 
compared to normal animals.  
For safety evaluation on systemic toxicity of repeated dosing of 
standardized JCP-allergen extract, 26 weeks repeated study using rodent by oral 
administration was conducted. Oral administration was selected with 
considering the route in clinical use, SLIT-swallow. The rats were used for this 
study because basic information could be provided from single dosed toxicity 
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and 2 week repeated toxicity (refer to section 3 of Chapter IV) in rats already 
conducted. The doses in this study were set based on the data in 2 weeks 
repeated toxicological study in rats. 
 
In Chapter III, systemic toxicology of repeated dosing of JCP-allergen 
extract during 26 weeks is discussed by the effect of clinical observation, body 
weight, food consumption, ophthalmoscopy, urinalysis, hematology, blood 
chemistry, and necropsy, organ weights and histopathology on the last day of 26 
weeks dosing period. Dosing period was determined to be 26 weeks according 
to the guideline on repeated toxicity required for the application to authority. 
AIT is generally considered to be continued more than 3 years (Bousquet et al., 
1998; Canonica et al., 2014), but the ratio of highest dose this study compared to 
clinical use is sufficient high to evaluate potency of JCP-allergen extract to 
induce systemic toxicity during repeated dose, it equals to 300-fold (10,000 
JAU/kg/day in rat versus 33 JAU/kg/day in human). 
 
This study was conducted according to the Guidelines for Repeated-dose 
Toxicity Studies in compliance with GLP Regulations specified by the Japanese 
Ordinance. All procedures employed in the experiments were approved by the 
Animal Ethics Committee of Mitsubishi Chemical Medience Corporation, 
Kumamoto, Japan, in accordance with laboratory animal welfare guidelines. 
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2  Materials and Methods 
2.1  Animals and husbandry 
Specific pathogen-free (SPF) Crl:CD (Sprague-Dawley) rats were 
supplied by Charles River Laboratories (Shiga, Japan) at 4 weeks of age. On 
arrival, body weights of 92 male and female rats were measured and were within 
the range of 70.1–90.8 g and 67.5–82.8 g, respectively. All animals were 
acclimatized to the testing environment for 12–14 days. Dosing of the test 
articles was initiated at 6 weeks of age. Animals were housed in stainless-steel 
cages under controlled environmental conditions with temperatures between 
22.1–24.5°C, relative humidity of 21.1–77.3%, air ventilation of 10–20 times/h, 
illumination 12-h per day (light on at 7:00 a.m. and off at 7:00 p.m.), and feed 
(certified diet CRF-1, Oriental Yeast Co., Ltd.) and water were available ad 
libitum. 
 
2.2  Standardized allergen extract of Japanese cedar pollen 
Standardized JCP-allergen extract is glycerinated JCP-allergen extract 
obtained by managed process and controlled by the content of Cry j 1, a major 
allergen protein of Japanese cedar pollen (Yasueda et al., 1983), and its allergen 
potency is expressed as Japanese allergen unit (JAU) defined based on skin 
reaction (Yasueda et al., 1996). Standardized JCP-allergen extract original 
solution 10,000 JAU/mL (10,000 JAU/mL JCP) is defined to contain 
7.3-21 μg/mL of Cry j 1(Yasueda et al., 1996). Test liquids of 200 and 2,000 
JAU/mL were formulated by dilution of 10,000 JAU/mL JCP to provide the 
indicated potency, respectively (Torii Pharmaceutical Co. Ltd., Tokyo, Japan). 
In a repeated 26-week oral toxicity study, 200, 2,000 and 10,000 JAU/mL 
of standardized JCP-allergen extract were used for oral administration. In 
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addition, 50% glycerin-containing sodium chloride was used for the vehicle 
control group. 
 
2.3  Treatment of test article 
Dose levels were selected based on the repeated 2-week oral toxicity 
study (non-GLP; refer to section 3 of Chapter IV) conducted with the test article. 
In this study, rats (12/sex-group) received daily oral doses of 200, 2,000 and 
10,000 JAU/mL of standardized JCP-allergen extract by gastric gavage at a 
constant dosing volume of 1 mL/kg for 26 weeks, resulting in 0 (vehicle control 
group), 200, 2,000, and 10,000 JAU/kg/day (Table 3).  
Oral administration was selected for administration, as this is the route 
used in the clinic (droplets is placed under the tongue, maintained for 2 minutes 
and then swallowed). In this study, 200 JAU/mL, 2,000 JAU/mL and 
standardized JCP-allergen extract original solution 10,000 JAU/mL (Torii 
Pharmaceutical Co. Ltd., Tokyo, Japan) were used. The vehicle consisted of 
JCP-allergen extract with 50% glycerin containing sodium chloride. The day of 
administration was defined as ‘day 1’. The week of administration was defined 
as ‘week 1’.  
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Table 3. Experimental design of safety evaluation on systemic toxicity 
of repeated dosed rat with JCP-allergen extract. 
Groups Treatment 
Dosed 
volume
(mL/kg)
Systemic 
exposure 
(JAU/kg) 
Number of animals 
Main  
study 
Recovery 
period b 
M  F  M  F  
Control Saline 1 0 12 12 6 6 
Vehicle control Vehicle a 1 0 12 12 6 6 
JCP 
200 JAU 
solution JCP 1 200 12 12 0 0 
2,000 JAU 
solution JCP 1 2,000 12 12 0 0 
10,000 JAU 
solution JCP 1 10,000 12 12 6 6 
  
M: male, F: female 
 JCP: allergen extract of Japanese cedar pollen 
 a 50% Glycerin, 5% Sodium chloride 
b Four weeks without dosing after 26 weeks dosing period.   
 
 
2.4  Clinical observations, body weights and food consumption 
All animals were observed twice daily (before dosing and after dosing) for 
clinical signs during the dosing period and once daily during the recovery period. 
Body weights and food consumption were measured immediately before the 
initiation of dosing on day 1, once a week during the dosing period and the 
recovery period. A feeding vessel containing food was weighed and set in the 
cage. The remaining diet was weighed at 24 h to calculate food consumption. 
 
2.5  Ophthalmoscopy 
Ophthalmoscopy was conducted on all animals from each group before 
the initiation of dosing: n=12 animals in week 13 and 26 before dosing per 
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group, and all animals during the recovery period. External eye observations 
were performed and followed by examination for light reflex using direct 
ophthalmoscope (Heine Optotechnik, Herrsching, Germany). After observation 
of the cornea, iris, conjunctiva, lens, and vitreous body using a slit-lamp (SL-15, 
Kowa Company, Nagoya, Japan), the ocular fundus was examined using 
binocular indirect ophthalmoscope (Heine Optotechnik) 
 
2.6  Urinalysis 
Urinalysis was performed for 12 animals per group at weeks 13 and 26 of 
the dosing period, and for all animals in the recovery period. Fresh urine was 
collected in the morning before dosing and the following parameters were 
examined using dipstick analysis: pH, protein, glucose, ketone bodies, bilirubin, 
occult blood and urobilinogen. Accumulated urine was collected overnight for 
24 h and the following parameters were examined: volume, color, osmotic 
pressure (Osmomat 030-D-RS, Genotec, Berlin, Germany), sodium, potassium 
and chloride ion concentration (EA07, A&T Corporation, Yokohama, Japan). 
Urine sediments were microscopically examined for epithelial cells, 
erythrocytes, leukocytes, casts and crystals. 
 
2.7  Hematology and blood chemistry 
Hematology was conducted using blood and plasma obtained at necropsy. 
The animals were fasted for 16–23 h before blood sampling. Ten hematological 
parameters were measured: numbers of leukocytes and erythrocytes, 
hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular 
hemoglobin, mean corpuscular hemoglobin concentration, reticulocyte counts, 
platelets and differential leukocyte counts, using a hematology system (ADVIA 
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120, Siemens Healthcare Diagnostics, Deerfield, IL). Two hematological 
parameters—prothrombin time and activated partial thromboplastin time—were 
determined by an autocoagulometer (Sysmex CA-5000, Sysmex Corporation, 
Kobe, Japan).  
Blood chemistry was conducted using sera obtained at necropsy. 
Estimations of various biochemical parameters: total protein, total bilirubin, 
aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total 
cholesterol, triglycerides, phospholipids, glucose, blood urea nitrogen, creatinine, 
inorganic phosphorus and calcium (Ca), were performed using an auto-analyzer 
(7170, Hitachi Ltd., Tokyo, Japan). Serum protein fractions (total protein × 
ratio), albumin and albumin/globulin ratio (A/G ratio) were estimated by an 
electrophoresis system (AES320, Beckman Coulter, Brea, CA). Sodium (Na), 
potassium (K) and chloride (Cl) were estimated by an electrolyte analyzer 
(EA07, A&T). 
 
2.8  Necropsy, organ weights and histopathology 
Following euthanasia by exsanguination from the abdominal inferior vena 
cava under pentobarbital anesthesia, all animals were examined in detail for 
gross lesions. Submandibular glands (with sublingual glands), liver, lungs (with 
bronchi), thymus, spleen, heart, kidneys, prostate gland, seminal vesicle, testes, 
epididymis, ovaries, uterus, pituitary, thyroids (with parathyroids), adrenals and 
brain were weighed after macroscopic examination, and the relative weight of 
each organ to the final body weight was calculated. For histopathology, after 
processing sections and staining with hematoxylin and eosin (HE) for light 
microscopy, the tongue, esophagus, stomach, duodenum, jejunum, ileum (with 
Peyer's patch), cecum, colon, rectum, parotid gland, pancreas, trachea, lower jaw 
lymph nodes, mesentery lymph node, aorta (chest), bladder, vagina, mammary 
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gland, spinal cord (cervical region), optic nerves, sciatic nerve, eyeballs, 
Harderian glands, biceps femoris muscle, sternum (with bone marrow), femoral 
fracture (with bone marrow), skin (lower abdomen) and the organs and tissues 
above that were examined macroscopically were analyzed histopathologically. 
Organ weights were expressed as relative weights versus body weights (100 g) 
measured at necropsy day. 
 
2.9  Statistical analysis 
Statistical analysis was performed for body weight, food consumption, 
urinalysis hematology, blood chemistry and organ weights using the 
MiTOX-PPL system (Mitsui Zosen Systems Research Inc., Chiba, Japan). For 
multiple comparisons, mean values and standard deviations were calculated for 
vehicle control group and treatment groups. The homogeneity of variances was 
evaluated using Bartlett’s test (significance level: 5%). In the case of 
homogeneous data, Dunnett’s multiple-comparison test was performed to 
compare with the vehicle control group. In the case of heterogeneous data, 
Steel’s multiple-comparison test was performed to compare with the vehicle 
control group. In cases of multiple comparisons, the two-sided test was used (P 
< 0.05, P < 0.01). For comparisons between two groups, mean values and 
standard deviations (SD) were calculated for control and vehicle control groups. 
The homogeneity of variances was evaluated using the F-test (significance level: 
5%). For homogeneous data, the Student’s t-test was used to compare with the 
control group. For heterogeneous data, Welch’s test was performed to compare 
with the control group. For comparison between the two groups, a two-sided test 
was used (P < 0.05, P < 0.01). 
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3  Results and Discussion 
3.1  Clinical observations, body weights and food consumption 
No test article related mortality was observed in any JCP-allergen extract 
treatment group and there were no treatment related changes in clinical 
observations, body weights (Figure 14) and food consumption (Figure 15) 
during the 26-week dosing period and 4-week recovery period. Non-treatment 
related changes, callus in hind limb, were observed in one male each from the 
vehicle control group and 2,000 JAU/kg group.  
 
 
Figure 14. Body weights of rats following oral administration of 
JCP-allergen extract.  
Rats were administered 200, 2,000 or 10,000 JAU/kg of JCP-allergen extract or vehicle (0 
JAU/kg) daily for 26 weeks. Values are expressed as mean ± SD of 18 animals for all groups 
except for female control group where n=17 and 200 JAU/kg and 2,000 JAU/kg groups where 
n=12. 
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Figure 15. Food consumption of rats following oral administration of 
JCP-allergen extract.  
Rats were orally administered 200, 2,000 and 10,000 JAU/kg of JCP-allergen extract or 
vehicle (0 JAU/kg) daily for 26 weeks. Values are expressed as mean ± SD of 18 animals in 
all groups except female controls where n=17 and 200 JAU/kg and 2,000 JAU/kg groups 
where n=12.  
#: p<0.05 (significantly different from control). 
*: p<0.05, **: p<0.01 (significantly different from 0 JAU/kg).  
 
3.2  Ophthalmoscopy and urinalysis 
Ophthalmologic examinations did not reveal treatment-related ocular 
lesions in any of the animals tested (data not shown). 
Urinalysis and microscopic examination of the sediment in the vehicle 
control group indicated increased sodium ions and chloride ions compared with 
the control group at 13 and 26 weeks, but the findings were not observed in the 
recovery period. No changes were observed in the JCP-allergen extract 
treatment groups compared with the vehicle control group at 13 weeks, 26 
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weeks and the recovery period (data not shown). It was considered that 
urinalysis indicated that sodium chloride in the vehicle of JCP-allergen extract 
increased sodium and chloride ion levels compared with the control group. This 
suggested that increases of sodium and chloride ions by urinalysis have no 
toxicological significance. 
 
3.3   Hematology and blood chemistry 
Results for hematology are shown in Table 4. Treatment-related changes 
were not observed in the JCP-allergen extract treatment group compared with 
the vehicle control group. The mean platelet counts was significantly increased 
in 10,000 JAU/kg group male rats but was not considered treatment related 
because the individual counts of rats (n=12) were within the range measured in 
the control group. The mean lymphocyte ratio was significantly increased in 
10,000 JAU/kg group male rats and the mean of monocyte ratio was 
significantly decreased in 200 JAU/kg, 2,000 JAU/kg and 10,000 JAU/kg group 
male rats. These were not considered treatment related changes because no 
changes were seen in counts of leucocytes and monocytes. Increased numbers of 
erythrocytes observed in 200 JAU/kg male rats was not dose-dependent. 
Results for blood chemistry are shown in Table 5. Treatment-related 
changes were not observed in JCP treatment groups compared with the vehicle 
control group. The following changes were not dose-dependent: decreased Cl in 
200 JAU/kg females, increased γ-globulin ratio in 2,000 JAU/kg males and 
decreased A/G ratio, albumin ratio and total bilirubin in 2,000 JAU/kg females. 
At the recovery period, no treatment related changes in hematology and blood 
chemistry were observed in the vehicle control group compared with the control 
group and between the JCP treatment group and vehicle control group (data not 
shown). 
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Regarding toxicokinetics, the amounts of Cry j 1, the major JCP allergen, 
were measured in the serum from rats treated with 10,000 JAU/mL at week 1, 
week 13 and week 26 before administration and 1, 2, 4, 8 and 24 h after 
administration. Cry j 1 protein was not detected in the sera at all the time points 
tested (data not shown), indicating proteins in the JCP-allergen extract 
administered orally were degraded immediately in the stomach. 
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Table 4. Hematological findings of rats following 26 weeks oral administration of  
JCP-allergen extract.  
Dosage (JAU/kg) Male Female Control 0 200 2,000 10,000 Control 0 200 2,000 10,000 
Leukocytes (103/L) 9.49±3.43 8.71±2.51 9.36±2.05 9.09±1.32 8.09±1.31  5.57±1.22 4.64#±0.88 4.56±0.80 4.82±1.25 4.95±1.04 
Erythrocytes (104/L)  840±47 846±24 876*±21 849±38 849±54  757±22 757±32 762±24 745±30 759±43 
Hemoglobin  
(g/dL) 14.8±0.8 14.7±0.5 15.0±0.5 14.8±0.5 14.7±0.8 
 
14.3±0.4 14.4±0.8 14.5±0.6 14.3±0.3 14.4±0.6 
Hematocrit (%) 42.4 ±2.2 41.9 ±1.3 42.9±1.0 42.8±1.6 42.0±2.0  40.4±1.1 40.8±2.0 41.0±1.3 40.2±0.9 40.6±1.8 
Mean corpuscular 
volume (fL) 50.5±1.5 49.5±1.0 49.1±1.1 50.4±1.5 49.6±2.4 
 
53.4±1.6 53.9±1.6 53.8±2.0 54.0±1.9 53.5±1.7 
Mean corpuscular 
hemoglobin:MCH (pg) 17.6±0.6 17.4±0.4 17.1±0.6 17.5±0.6 17.3±0.9 
 
18.8±0.7 19.1±0.5 19.1±1.0 19.1±0.7 19.0±0.6 
MCH concentration 
(g/dL) 34.9±0.6 35.1±0.3 34.8±0.6 34.7±0.4 34.9±0.5 
 
35.3±0.5 35.4±0.6 35.4±0.8 35.5±0.8 35.4±0.5 
Reticulocytes (%) 2.1±1.1 1.8±0.2 1.7±0.3 1.8±0.5 2.2±1.9  1.9±0.4 1.9±0.3 1.8±0.4 1.9±0.2 1.9±0.2 
 Platelets  
(104/L) 104.9±15.5 95.0±6.8 97.4±13.1 101.8±9.0 105.7*±12.0
 
92.9±10.5 94.9±8.5 88.4±7.2 96.7±11.5 98.6±7.2 
 Prothrombin time 
(sec) 11.5±1.2 11.5±1.5 11.6±1.3 11.2±0.5 11.0±0.4 
 
9.5±0.2 9.3±0.2 9.3±0.2 9.4±0.3 9.3±0.2 
Activated partial 
thromboplasmin time 
(sec) 
20.8±1.7 20.9±2.2 21.2±1.4 21.3±1.0 21.2±1.4 
 
18.4±1.3 18.6±1.0 18.5±0.8 19.2±0.8 18.7±1.6 
Eosinophils (%) 1.9±1.0 1.9±0.5 1.8±0.4 1.7±0.6 1.9±0.6  2.2±1.1 2.1±0.7 2.0±0.6 1.8±0.5 1.8±0.8 
Neutrophils (%) 29.3±13.5 24.9±8.6 20.2±7.5 19.4±3.3 18.8±4.4  20.3±9.4 18.2±4.4 19±9.4  26.4±10.8 17.9±7.4 
Lymphocytes (%) 64.7±14.2 68.9±8.6 74.6±7.7 75.5±4.1 75.6*±5.2  73.2±10.0 75.8±4.6 75.0±10.2 67.3±12.0 76.7±8.5 
Basophils(%) 0.5±0.1 0.5±0.1 0.5±0.1 0.5±0.1 0.5±0.1  0.4±0.2 0.5±0.1 0.4±0.1 0.5±0.1 0.4±0.2 
Monocytes (%) 2.7±0.7 3.2±0.9 2.3*±0.5 2.1**±0.6 2.3*±0.8  3.0±0.7 2.5±0.5 2.7±0.7  3.0±1.2 2.6±0.9 
Large unstained cells 
(%) 1.0±0.6 0.8±0.2 0.8±0.3 0.8±0.5 1.0±0.5 
 
0.9±0.5 0.9±0.6 0.9±0.5 1.0±0.7  0.7±0.4 
 
Values are expressed as mean ± SD of 12 animals in each group.  
#: p<0.05 (significantly different from control).  
*: p<0.05, **: p<0.01 (significantly different from 0 JAU/kg).  
Chapter III. SYSTEMIC TOXICOLOGY  
 49
Table 5.  Blood chemical findings of rats following 26 weeks oral administration of JCP-allergen extract. 
Dosage (JAU/kg) Males  Females Control 0 200 2,000 10,000  Control 0 200 2,000 10,000 
Total protein (g/dL) 5.7±0.2 5.8±0.3 6.0±0.3 5.9±0.2 5.9±0.2  6.4±0.5 6.4±0.4 6.5±0.3 6.5±0.4 6.6±0.3 
Albumin (g/dL) 2.69±0.17 2.76±0.14 2.83±0.17 2.75±0.11 2.8 ± 0.16  3.65 ±0.40 3.68±0.33 3.78±0.23 3.61±0.33 3.79±0.20
A/G ratio 0.89±0.09 0.92±0.07 0.91±0.08 0.87±0.06 0.89 ± 
0.08 
 
1.33 ±0.13 1.38±0.13 1.4±0.13
1.25*±0.1
6 
1.36±0.09
1-Globulin (%) 24.2±2.0 25.1±1.8 24.7±2.3 24.6±1.8 25.2±2.1  17.2±1.1 16.5±1.9 16.4±1.4 17.7±1.1 16.9±1.4
2-Globulin (%) 5.4±0.8 5.1±0.5 5.0±0.4 5.2±0.5 4.9±0.6  4.9±0.5 4.8±0.6 4.9±0.6 5.0±0.6 4.6±0.6 
-Globulin (%) 17.5±1.9 17.1±0.9 17.2±0.8 17.5±1.1 17.3±0.9  14.5±1.8 14.2±1.0 14.1±1.2 15.0±1.9 14.3±1.0
-Globulin (%) 5.9±1.6 5.0±1.0 5.5±0.8 6.2*±1.1 5.5±1.0  6.5±1.0 6.6±1.3 6.4±0.7 7.1±1.1 6.7±0.8 
Albumin (%) 47.0±2.6 47.7±2.0 47.6±2.2 46.6±1.9 47.1±2.1  56.9±2.5 57.9±2.3 58.2±2.2 55.2*±3.1 57.6±1.6
Total bilirubin (mg/dL) 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0  0.1±0.0 0.1±0.0 0.1±0.0 0.0*±0.0 0.1±0.1 
Aspartate 
aminotransferase (IU/L) 90±31 83±10 79±17 81±26 78±8 
 
103±58 103±36 148±159 146±142 106±56 
Alanine 
aminotransferase (IU/L) 29±16 21±4 23±6 26±19 21±4 
 
36±21 35±18 53±57 56±64 40±24 
Alkaline phosphatase 
(IU/L) 138±33 123±13 124±24 120±24 130±33 
 
53±12 51±12 52±11 54±21 51±12 
Total cholesterol (mg/dL) 85±19 78±14 87±21 76±11 89±16  94±25 86±12 98±19 100±20 91±9 
Triglycerides (mg/dL) 78±39 76±31 92±33 67±25 87±47  39±18 41±21 43±15 43±28 45±27 
Phospholipids (mg/dL) 140±24 131±15 143±23 127±15 142±22  182±39 172±25 189±30 190±35 182±21 
Glucose (mg/dL) 125±13 128±12 126±9 123±8 126±23  119±6 117±13 116±6 117±6 120±9 
Blood urea nitrogen 
(mg/dL) 16.2±3.7 16.5±3.2 14.8±2.0 15.8±2.1 16.9±1.4 
 
16.1±2.4 17.8±2.9 16.3±2.4 15.3±1.7 17.1±3.4
Creatinine (mg/dL) 0.4±0.1 0.4±0.1 0.4±0.0 0.4±0.1 0.4±0.0  0.5±0.1 0.5±0.1 0.5±0.1 0.5±0.0 0.5±0.1 
Inorganic phosphorus 
(mg/dL) 6±0.7 5.9±0.7 5.7±0.6 6.0±0.4 5.9±0.6 
 
4.5±0.7 4.6±0.9 4.9±0.8 4.8±0.9 4.9±1.0 
Ca (mg/dL) 10.2±0.3 10.2±0.3 10.4±0.3 10.2±0.3 10.4±0.3  10.5±0.3 10.4±0.4 10.6±0.3 10.5±0.2 10.5±0.2
Na (mEq/L) 146±0.8 145.9±0.7 145.8±0.9 146.4±0.9 145.9±1.0  144.4±0.7 144.6±0.9 143.6±1.3 144.6±1.1 144.9±0.9
K (mEq/L) 4.51±0.18 4.53±0.28 4.42±0.16 4.57±0.17 4.67±0.21  3.89±0.21 4.05±0.21 3.95±0.21 4.0±0.23 3.99±0.32
Cl (mEq/L) 106.4±1.4 106.1±1.5 105.9±1.1 106.4±1.3 106±1.1  106.8±1.5 107.6±1.5 106.2*±1.1 107.2±0.8 107.4±1.1
 
Values are expressed as mean ± SD of 12 animals in each group. 
*: p<0.05 (significantly different from 0 JAU/kg)
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3.4   Necropsy, organ weights and histopathology 
No gross abnormalities were detected for rats in any group by necropsy at 
the treatment period and recovery period (Table 6). Callus in hind limbs were 
observed in one male each from the vehicle control group and 2,000 JAU/kg 
group corresponding to the clinical observations. A yellow-brown neoplasm was 
observed in the abdominal cavity of a male rat in the control group. 
 
Table 6. Findings in necropsy of rats following 26 weeks oral 
administration of JCP-allergen extract. 
Dosage 
(JAU/kg) 
 Male Female 
Control 0 200 2,000 10,000 Control 0 200 2,000 10,000
Others      
Abdominal 
cavity 
Mass, 
Yellow 
-brown 
1 0 0 0 0 0 0 0 0 0 
Extremity Corn, hindlimb 0 1 0 1 0 0 0 0 0 0 
 
Values are expressed as the number of animals observed with indicated findings in 12 animals 
of each group. 
No appreciable changes in all other organs and tissues. 
 
There were no treatment-related differences in organ weights between the 
vehicle control and 10,000 JAU/kg groups (Figure 16). A decrease in relative 
organ weight of the thymus was observed in 200 JAU/kg group females and 
increased relative organ weight of the kidney (left) was observed in 2,000 
JAU/mL males. These were not dose-dependent changes.  
  
Chapter III. SYSTEMIC TOXICOLOGY  
 51
A) Male
 
B) Female 
 
Figure 16. Organ weights of rats following 26 weeks oral administration 
of JCP-allergen extract.  
 
Rats were orally administered 200, 2,000 and 10,000 JAU/kg of JCP-allergen extract or 
vehicle (0 JAU/kg) daily for 26 weeks. Values are expressed as mean ± SD of 12 animals in 
each group. #: p<0.05 (significantly different from control). *: p<0.05 (significantly different 
from 0 JAU/kg).  
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Results for histopathology are shown in Table 7. Histopathology revealed 
no systemic toxicological changes in the organs of vehicle and 10,000 JAU/kg 
groups, although some changes in organs occurred sporadically. Except for the 
stomach findings, these changes were considered incidental because they 
occurred in the control or vehicle control groups, or with a comparable 
frequency and similar level to the control group.  
The stomach is the first organ to come into contact with JCP-allergen 
extract administered orally. Hyperplasia in the forestomach and increased 
globule leukocytes in the glandular stomach were observed at comparable levels 
between the vehicle control group and 10,000 JAU/kg group. The stomach 
findings disappeared in recovery period suggesting temporary changes. 
Histopathology at the recovery period indicated no changes (data not shown). 
Regarding hyperplasia, it might be caused by irritation from glycerin (Staples et 
al., 1967) in the vehicle solution because it was not observed in the control 
group administered saline and the frequency and grade of hyperplasia were 
comparable between vehicle and 10,000 JAU/mL treated group. Of note, it is 
not appropriate to extrapolate the findings observed in the forestomach, a unique 
organ in rodents, to potential local changes in the stomach of humans. Regarding 
globule leukocytes, it is a large intra-epithelial cell, which is thought to be 
derived from a common precursor of mast cells (Ikeda and Yamashita, 1993), 
arising during intestinal nematode infections in rodents and ruminants and with 
granulated lymphocytes (Huntley, 1992). The mild increase of globule 
leukocytes in the glandular stomach observed in this study might be caused by 
irritation from glycerin in the vehicle solution. In addition, increased numbers of 
globule leukocytes are associated with the presence of lesions in the GI tract 
(Narama et al., 1999) .These findings occurred in the stomach of rats of the 
repeated 26-week oral toxicity study were toxicologically mild and were not 
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observed after the 4-week recovery period in the control and JCP-allergen 
extract treatment groups. 
 
Table 7. Histopathological findings of rats following 26 weeks oral 
administration of JCP-allergen extract. 
Organ/Tissue Finding 
Dose (JAU/kg/day) 
Male Female 
Control
(Saline)
0 10,000
Control 
(Saline) 
0 10,000
 
Esophagus    0 0 0 0 0 0 
 Stomach Hyperplasia,squamous epithelium,forestomach,limiting ridge 0 3 4 0 4 3 
  Cyst,glandular stomach 0 0 0 1 1 0 
  Erosion,glandular stomach 0 1 1 0 1 0 
  Globule leukocyte,increased,glandular stomach 0 3 5 0 2 1 
 
Sublingual 
gland Cellular infiltration,lymphocyte 0 0 0 0 0 1 
 Parotid gland Cellular infiltration,lymphocyte 3 2 2 1 1 1 
 Liver Hemorrhage,focal 0 0 2 0 0 0 
  Necrosis,hepatocyte,focal 0 0 0 1 1 0 
  Cellular infiltration,mononuclear cell 7 5 7 2 2 2 
  Fibrosis,focal 1 1 0 0 0 0 
 Pancreas Atrophy,acinus 3 0 3 0 0 0 
  Focus,acinar cell,basophilic 1 0 0 0 0 0 
  Deposit,pigment,yellow-brown 2 0 2 0 0 0 
  Cellular infiltration,eosinophil 0 1 1 1 0 0 
  Cellular infiltration,lymphocyte 4 5 1 2 5 4 
  Fibrosis,islet 2 1 3 0 0 0 
 Lung Metaplasia,osseous 2 0 1 0 0 0 
  Accumulation,foam cell 1 2 3 2 2 1 
  Mineralization,artery 1 2 2 2 3 4 
 Spleen Hematopoiesis,extramedullary 1 0 2 0 0 0 
 
Bone 
marrow 
(femur) 
Hematopoiesis,increased 1 0 0 0 0 0 
 Heart Cellular infiltration,mononuclear cell 3 3 0 0 1 0 
 Kidney Tubule,basophilic 3 5 3 - - - 
  Deposit,pigment,tubule,yellow-brown 1 0 2 - - - 
  Cast,proteinaceous 2 3 3 - - - 
  Cellular infiltration,pelvis,inflammatory 1 1 0 0 0 1 
  Cellular infiltration,lymphocyte 6 5 7 0 1 3 
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Groups contained 12 rats. The organs and tissues of the 200 JAU/mL and 2,000 JAU/mL 
groups were not examined. The organs and tissues of 200 JAU/mL and 2,000 JAU/mL group 
are not examined. .No appreciable changes in all other organs and tissues. 
  
  Cyst    1 1 0 
  Mineralization 3 1 2 1 1 0 
 
Urinary 
bladder 
Cellular 
infiltration,submucosa,lymphocyte 1 0 0 0 0 0 
 Testis  0 0 0 - - - 
 Epididymis  0 0 0 - - - 
 Prostate Cellular infiltration,lymphocyte 7 2 7 - - - 
 Ovary Cyst - - - 4 3 5 
 
Mammary 
gland Mineralization 1 0 0 0 0 0 
  Hyperplasia,lobular 0 0 0 1 0 0 
 Pituitary Hyperplasia,focal 1 0 0 0 0 0 
  Cyst 0 1 0 2 0 0 
 Thyroid Remnant,ultimobranchial body 1 1 2 1 4 2 
  Hyperplasia,C cell,focal 0 0 0 1 0 0 
  Cyst 0 0 0 0 1 1 
 Adrenal Vacuolation,cortical cell,zona fasciculata,focal 1 0 0 0 0 0 
 Cerebellum Cellular infiltration,chorioid plexus,lymphocyte 0 0 0 1 0 0 
 Eye Mineralization,cornea 1 1 2 0 0 0 
 
Harderian 
gland Cellular infiltration,lymphocyte 2 1 2 4 5 1 
 Integument Crust 0 0 1 0 0 0 
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4  Summary 
A 26-week repeated oral dose toxicity study in rats was conducted with 
standardized JCP-allergen extract to evaluate its safety for application to SLIT. 
The route of dosing was selected based on the human therapeutic route of 
JCP-allergen extract that is SLIT-swallow. Rats were administered JCP-allergen 
extract at doses of 200, 2,000 and 10,000 JAU/kg-day by body weight. The 
effect of JCP-allergen extract was compared with a vehicle control group (50% 
glycerin containing sodium chloride) to evaluate the test substance and the 
vehicle control group was compared with control group (saline) to evaluate the 
vehicle.  
There were no JCP-allergen extract related toxicologically relevant 
changes in clinical signs, body weight change, food consumption, 
ophthalmoscopy, urinalysis, hematology, blood chemistry, necropsy, organ 
weights and histopathology although slight local changes caused by irritation 
from the vehicle were observed at the administration site. 
Therefore, NOAEL was greater than 10,000 JAU/kg/day for systemic 
toxicity, equivalent to 300-fold the human dose.  
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Chapter IV. LOCAL IRRITATION OF 
ALLERGEN EXTRACT OF JAPANESE 
CEDAR POLLEN  
 
1  Introduction 
In SLIT, the allergen extract is placed under the tongue for 1 or 2 minutes 
and then swallowed (SLIT-swallow) or spat out (SLIT-spit). Based on clinical 
results and pharmacokinetic considerations, only SLIT-swallow is currently 
performed (Canonica and Passalacqua, 2003). Oral irritative reactions are 
distinctive adverse events in SLIT that include stomatitis and throat irritation 
induced in the early stages of treatment, in response to the allergen, which 
activates the immune system. Stomatitis and throat irritation were reported as 
adverse events in a clinical trial using a sublingual tablet of timothy pollen 
extract in Europe (Nelson et al., 2011). 
In the case of standardized JCP-allergen extract, the allergen droplet is 
placed under the tongue for 2 minutes and swallowed (SLIT-swallow). Based on 
such as clinical usage, two selected sites which are oral area and GI tract were 
examined in local irritation studies. Oral mucosa is first-of-contact site of 
allergen extract administered sublingual administration because of generally 
used species for irritation study as well as dogs. Mucosa of GI tract is contact 
site after swallowing of allergen extract in SLIT. Rats were used for irritation 
study of GI tract after oral administration because same species was used in 26 
weeks repeated toxicological study conducted by oral administration. 
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In Chapter IV, the potential of standardized JCP-allergen extract to cause 
oral mucosal irritation was mentioned first in the study of rabbits by repeated 
sublingual dosing for 7 days of 2,000 JAU/mL, the maximum dose used in the 
clinic (Mitobe et al., 2012). The optimal volume of administration was 
determined in a preliminary study to ensure the maximum volume did not leak 
from the mouth or accidentally be ingested. The administration time to the 
sublingual area of rabbits was 20 min. It was longer than the 2 min used for 
human clinical application because the increased grade of lesion is dependent on 
administration time in oral mucosal irritation studies using rabbits (Ohbayashi et 
al., 1988). 
After that, the potential to cause GI tract irritation was also discussed in 
the study of rats by repeated oral dosing for 14 days of 10,000 JAU/mL (stocked 
solution of standardized JCP-allergen extract 2,000 JAU/mL and 200 JAU/mL) 
(Mitobe et al., 2011). Mucosal irritation of JCP-allergen extract in GI tract was 
evaluated by necropsy and histopathology conducted on last day of repeated 
dosing, compared with the vehicle control groups. In addition at this study, 
systemic toxicity was evaluated in same animals as well as local irritation in GI 
tract, clinical observation, body weight, food consumption, hematology, blood 
chemistry, necropsy, organ weight and histopathology. The data obtained from 
systemic toxicological examination was considered for dose setting in 26 
repeated toxicological study by oral administration in the rats. 
 
The study for oral mucosal irritation in the rabbits was conducted in 
compliance to GLP regulations specified by the Japanese Ordinance. Both 
studies of oral mucosal irritation in the rabbits and mucosal irritation of GI tract 
Chapter IV. LOCAL IRRITATION  
 58
in the rats were conducted with approval of the Institutional Animal Care and 
Use Committee of Mitsubishi Chemical Medience Corporation in accordance 
with laboratory animal welfare guidelines.  
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2  Irritation to Oral Mucosa in Rabbits  
2.1  Materials and Methods 
(1) Animals and husbandry 
SPF male Kbs: New Zealand White rabbits of 17 weeks of age were 
supplied by Kitayama Labes Co., Ltd. (Nagano, Japan). Upon arrival, ten male 
rabbits were weighed (range of 2,829–3,315 g). All animals were acclimatized 
to the testing environment for 6 days. Dosing of the test article was initiated at 
18 weeks of age. The body weight range at initiation of dosing was 3,056–3,485 
g. Animals were housed in stainless-steel cages under controlled environmental 
conditions with temperatures between of 23.1–24.4°C, relative humidity of 
47.6–61.6%, air ventilation of 10–20 times/h, illumination 12-hour per day (light 
on at 7:00 a.m. and off at 7:00 p.m.), and feed (LRC6, Oriental Yeast Co., Ltd.) 
and water were available ad libitum.. 
(2) Standardized allergen extract of Japanese cedar pollen 
Standardized JCP-allergen extract is glycerinated JCP-allergen extract 
obtained by managed process and controlled by the content of Cry j 1, a major 
allergen protein of Japanese cedar pollen (Yasueda et al. 1983), and its allergen 
potency is expressed as Japanese allergen unit (JAU) defined based on skin 
reaction (Yasueda et al., 1996). Standardized JCP-allergen extract original 
solution 10,000 JAU/mL (10,000 JAU/mL JCP) is defined to contain 
7.3-21μg/mL of Cry j 1(Yasueda et al., 1996). Test liquids of 200 and 2,000 
JAU/mL were formulated by dilution of 10,000 JAU/mL JCP to provide the 
indicated potency, respectively (Torii Pharmaceutical Co. Ltd., Tokyo, Japan). 
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For the oral mucosal irritation study, 2,000 JAU/mL of standardized 
JCP-allergen extract was administered sublingually, as the maximum dose 
used in the maintenance phase of SLIT in JC pollinosis. 
 
(3) Treatment of test article 
Three male rabbits per group received daily sublingual administration for 7 
days under sedation by intramuscular injection of medetomidine, with saline 
(control group), 50% glycerin solution containing sodium chloride (vehicle 
control group) or JCP-allergen extract (2,000 JAU/mL). The 0.2 mL test 
solution was administered to the sublingual area for 20 min followed by washing 
with 30 mL of saline. The 2,000 JAU/mL was used in this study which is 
maximum dose in the maintenance phase of SLIT in JC pollinosis. The dosing 
volume of 0.2 mL/head was the maximum technical dose for sublingual 
administration to rabbits, resulting in 400 JAU/head. 
Sublingual administration was selected as it is the intended clinical route. 
 
(4) Clinical observations and body weights 
All animals were observed twice daily (before dosing and after dosing) for 
clinical signs during the dosing period (from days 1 to 7) and once at day 8. 
Body weights were measured immediately before the initiation of dosing on day 
1 and on the last day of dosing (day 8).   
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(5) Macroscopic observation of administration site 
Macroscopic observation of the administration site was performed under 
sedation before administration from days 1 to 8. The administration site in the 
oral cavity was estimated for irritative scores according to Ohbayashi’s criteria 
in rabbits (Ohbayashi et al., 1988) shown in Table 8. 
 
Table 8.  Scale for scoring acute oral reactions in the rabbits sublingual 
mucosa under macroscopic observation. 
Findings in administration site Score 
No reaction 0 
Slight erythema (barely perceptible) 1 
Clear erythema (well defined erythema) 2 
Slight white fur (barely perceptible) 3 
Mild white fur (well defined white fur) 4 
Moderate white fur (thick white fur raised less than one half) 5 
Severe white fur (thick white fur raised more than one-half) 6 
Ohbayashi et al., 1988 
 
(6) Histopathology of administration site 
Histopathology was conducted at the administration site in the oral area of 
the rabbits. At day 8 after clinical observation, all rabbits were anesthetized with 
intravenous injection of sodium pentobarbital (30 mg/kg) followed by 
macroscopic observation of administration site, and euthanasia was performed. 
Oral mucosal tissues including tongue, mouth floor and buccal area (Figure 17) 
were removed and fixed in 10 vol% neutral buffered formalin. The mucosa 
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tissues were embedded in paraffin, sectioned, stained with HE and examined 
microscopically 
 
A) Photo of oral area of rabbit         B) Corresponding cartoon 
  
Figure 17. Administration site including sublingual, mouth floor and 
buccal area of rabbit. 
The numbers in photo abd cartoon mean 1; sublingual, 2; mouth floor, 3; buccal area. Red 
lines in photo and blue lines in cartoon show cut side for histopathology. This photo was 
taken in preliminary study. 
  
1
2
3
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2.2  Results and Discussion 
We confirmed the irritative response caused by positive control observed in 
the oral mucosa of rabbits administered sublingually for 7 days as preliminary 
study. Positive control, 35% SLS, showed slight white fur (score 3) in 
macroscopic observation from day 2 to day 7. Histopathological analysis was 
conducted on day 8 and H&E straining showed slight erosion and invasion of 
heterophil in mucosa of mouth floor (Figure 18 A).  
Oral mucosal irritation of JCP-allergen extract was evaluated with repeated 
sublingual dose study in rabbits. There were no treatment-related changes in the 
clinical observations and body weight of treated rabbits during the treatment of 
2,000 JAU/mL of JCP-allergen extract (Table 9).  
 
Table 9. Macroscopic observations of sublingual/buccal cavity of rabbits 
following 7 days sublingual administration of JCP-allergen extract.  
Body weights (g) Scoring of oral mucosa 
Day 1 Day 8 Day 1 Day 8 
Control 
(Saline) 3197 ± 185 3206 ± 254 0 ± 0 0 ± 0 
Vehicle  3295 ± 219 3244 ± 200 0 ± 0 0 ± 0 
JCP  
2,000 JAU 
solution 
3195 ± 152 3132 ± 86 0 ± 0 0 ± 0 
 
Values are expressed as mean ± SD of three animals in each group.  
JCP 2,000 JAU solution: Standardized JCP-allergen extract with allergen potency of 2,000 
JAU/mL 
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The macroscopic observation of the administration site revealed no 
irritation in the sublingual mucosa of animals throughout the dosing period. In 
addition, histopathology of oral mucosal tissues including tongue, buccal and 
mouth floor revealed no abnormalities in the treatment groups, although there 
was mild lymphocytic infiltration in the mucosa of the mouth floor of one 
animal in the control group (Figure 18B). 
 
 
   
Figure 18. H&E staining of oral mucosa sections from rabbits following 
7 days sublingual administered of JCP-allergen extract.  
Three rabbits/group were administered A) 0.1 mL of 35 w/v% sodium lauryl sulphate (SLS) 
solution for 10 min sublingually for 7 days and B) 0.2 mL of 2,000 JAU/mL JCP-allergen 
extract (400 JAU/head), vehicle (0 JAU/head) or saline sublingually for 20 min daily in 7 
days. The bars indicate 100 μm.  
 
Irritation study is one of the toxicological studies in the study package for 
new drug application to authority. The purpose of the study is to evaluate a 
physical property of the drug its self, so normal animals are used for the 
investigation. Other burden allergen with induction of allergic asthma and 
B) JCP treatment  A) Positive control; 
35%SLS 
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rhinitis, house dust mite, was evaluated on oral mucosal irritation in the normal 
dog. No changes were observed up to 60 mg/site/day for 28 days repeated 
sublingual administration (Ohashi-Doi et al., 2012).   
Local irritative response is main adverse event observed in SLIT with 
allergic patients. In the aspect of character of allergen extract such as local 
exposure and allergic potency, induction of local reaction in administration area 
of sensitized animal or human are quite reasonable. In fact, several local 
irritative reactions such as oral edema, stomatitis, irritation of pharynx and 
itchiness in mouth were reported in the clinical trial with standardized 
JCP-allergen extract (Torii Pharmaceutical Co. Ltd., Pharmaceutical interview 
form; CEDARTOLEN® Sublingual Immunotherapy Droplet of Japanese Cedar 
Pollen). Further studies are required to examine local irritation in sensitized 
animals for evaluation of the irritation in allergic patients. 
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2.3  Short Summary 
The potential of JCP-allergen extract to cause oral mucosal irritation was 
evaluated in rabbits by repeated dosing for 7 days of 2,000 JAU/mL, the 
maximum dose used in the clinic. We confirmed that irritative response of 
positive control (35% SLS solution) was induced in the oral mucosa of rabbit 
following sublingually repeated treatment for 7 days. In this study, the volume 
of administration was 0.2 mL as maximum volume did not leak from the mouth 
or accidentally be ingested. The administration time to the sublingual area of 
rabbits was 20 min which is ten-fold longer than the 2 min used for human 
clinical application.  
There were no treatment-related changes by macroscopic observation of 
the administration site throughout the dosing period and by histopathology of 
oral mucosal tissues including tongue, buccal and mouth floor. It suggested no 
local irritation of the sublingual/buccal mucosa occurred in healthy rabbits after 
1 week repeated sublingual treatment with JCP-allergen extract drug product 
with 10-times longer application than for clinical use. Further study is required 
in JCP-allergen extract -sensitized animals to evaluate the local irritation that 
appeared during SLIT in patients with JC pollinosis. 
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3  Irritation to Mucosa of Gastrointestinal Tract in Rats 
3.1  Materials and Methods 
(1) Animals and husbandry 
Specific pathogen-free (SPF) Crl:CD (Sprague-Dawley) rats were 
supplied by Charles River Laboratories (Shiga, Japan) at 5 weeks of age. On 
arrival, body weights of 20 male rats were measured and were within the range 
of 117.3–134.9 g. All animals were acclimatized to the testing environment for 5 
days. Dosing of the test articles was initiated at 6 weeks of age. Animals were 
housed in stainless-steel cages under controlled environmental conditions with 
temperatures between 23.3–24.5°C, relative humidity of 43.6–62.0%, air 
ventilation of 10–20 times/h, illumination 12-h per day (light on at 7:00 a.m. and 
off at 7:00 p.m.), and feed (certified diet CRF-1, Oriental Yeast Co., Ltd.) and 
water were available ad libitum. 
(2) Allergen extract of Japanese cedar pollen 
Standardized JCP-allergen extract is glycerinated JCP extract obtained by 
managed process and controlled by the content of Cry j 1, a major allergen 
protein of Japanese cedar pollen (Yasueda, et al. 1983), and its allergen potency 
is expressed as Japanese allergen unit (JAU) defined based on skin reaction 
(Yasueda et al., 1996). Standardized JCP-allergen extract original solution 
10,000 JAU/mL (10,000 JAU/mL JCP-allergen extract) is defined to contain 
7.3-21μg /mL of Cry j 1(Yasueda et al. 1996).  
For the irritation study to mucosa of GI tract in rat, 10,000 JAU/mL 
JCP-allergen extract was administered orally in each dose levels. 
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(3) Treatment of test article 
Three male rats per group received daily oral administration of 10,000 
JAU/mL of standardized JCP-allergen extract by gastric gavage at a constant 
dosing volume of 0.1, 0.5 and 2.5 mL/kg for 14 days, resulting in 200, 2,000, 
and 1,000, 5,000 and 25,000 JAU/kg/day (Table 10). Animals of vehicle control 
group received daily oral administration of 50% glycerin solution containing 
sodium chloride in same way as treated group in 0.1, 0.5 and 2.5 mL/kg 
respectively, for each controls. Oral administration route was selected as it is the 
intended clinical route. The day of administration was defined as ‘day 1’.  
 
Table 10. Experimental design of irritation study to mucosa of 
gastrointestinal tract in rats 
Groups Treatment 
Dosed 
volume 
(mL/kg) 
Exposure 
(JAU/kg) Number of animals 
(Male) Systemic ( /kg) 
Localc 
( /site) 
Vehicle 
control 
-1 Vehiclea 0.1 0 0 3 
-2 Vehiclea 0.5 0 0 3 
-3 Vehiclea 2.5 0 0 3 
JCP 10,000 
JAU solution 
-1 JCPb 0.1 1,000 250 3 
-2 JCPb 0.5 5,000 1,250 3 
-3 JCPb 2.5 25,000 6,250 3 
 
 a 50% Glycerin, 5% Sodium chloride 
b Standardized JCP-allergen extract with allergen potency of 10,000 JAU/mL 
c Calculated based on 250 g of rat body weight  
 
(4) Clinical observations, body weights and food consumption 
All animals were observed twice daily (before dosing and after dosing) for 
clinical signs during the dosing period (from days 1 to 14). Body weights were 
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measured immediately before the initiation of dosing on day 1, 4, 8, 11 and on 
the last day of dosing (day 14). A feeding vessel containing food was weighed 
and set in the cage. The remaining diet was weighed at 24 h to calculate food 
consumption on 1, 4, 8, 11 and on the last day of dosing (day 14). 
(5) Hematology and blood chemistry 
Hematology was conducted using blood and plasma obtained at necropsy. 
The animals were fasted for 19–22 h before blood sampling. Ten hematological 
parameters were measured: numbers of leukocytes and erythrocytes, 
hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular 
hemoglobin, mean corpuscular hemoglobin concentration, reticulocyte counts, 
platelets and differential leukocyte counts, using a hematology system (ADVIA 
120, Siemens Healthcare Diagnostics, Deerfield, IL, USA). Two hematological 
parameters—prothrombin time and activated partial thromboplastin time—were 
determined by an autocoagulometer (Sysmex CA-5000, Sysmex Corporation, 
Kobe, Japan).  
Blood chemistry was conducted using sera obtained at necropsy. 
Estimations of various biochemical parameters: total protein, total bilirubin, 
aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total 
cholesterol, triglycerides, phospholipids, glucose, blood urea nitrogen, creatinine, 
inorganic phosphorus and Ca, were performed using an auto-analyzer (7170, 
Hitachi Ltd., Tokyo, Japan). Serum protein fractions (total protein × ratio), 
albumin and A/G ratio were estimated by an electrophoresis system (AES320, 
Beckman Coulter, Brea, CA, USA). Na, K and Cl were estimated by an 
electrolyte analyzer (EA07, A&T). 
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(6) Necropsy, organ weights and histopathology 
Following euthanasia by exsanguination from the abdominal inferior vena 
cava under pentobarbital anesthesia, all animals were examined in detail for 
gross lesions. Submandibular glands (with sublingual glands), liver, lungs (with 
bronchi), thymus, spleen, heart, kidneys, prostate gland, seminal vesicle, testes, 
epididymis, ovaries, uterus, pituitary, thyroids (with parathyroids), adrenals and 
brain were weighed after macroscopic examination, and the relative weight of 
each organ to the final body weight was calculated. For histopathology, after 
processing sections and staining with hematoxylin and eosin (HE) for light 
microscopy, the esophagus, stomach, duodenum, jejunum, ileum, cecum, colon, 
rectum, and the organs and tissues above that were examined macroscopically 
were analyzed histopathologically in Vehicle-3 and JCP-3 groups. Organ 
weights were expressed as relative weights versus body weights (100 g) 
measured at necropsy day in all groups. 
(7) Statistical analysis 
Statistical analysis was performed for body weight, food consumption, 
hematology, blood chemistry and organ weights using the MiTOX-PPL system 
(Mitsui Zosen Systems Research Inc.). For multiple comparisons, mean values 
and standard deviations were calculated for vehicle control group and treatment 
groups. For comparisons between two groups, mean values and standard 
deviations (SD) were calculated for each vehicle control groups. The 
homogeneity of variances was evaluated using the F-test (significance level: 
5%). For homogeneous data, the Student’s t-test was used to compare with the 
vehicle control group. For heterogeneous data, Welch’s test was performed to 
compare with the control group. For comparison between the two groups 
(significance level: 5%), a two-sided test was used (P < 0.05, P < 0.01) 
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3.2  Results and Discussion 
No test article related mortality was observed in any JCP-allergen extract 
treatment group and there were no treatment related changes in clinical 
observations, body weights (Figure 19) and food consumption (data not shown) 
during the 14-day dosing period.  
 
 
Figure 19. Body weights of rats following oral administration of 
JCP-allergen extract. 
Rats were administered 200, 2,000 or 10,000 JAU/kg of JCP-allergen extract or vehicle (0 
JAU/kg) daily for 26 weeks. Values are expressed as mean ± SD of 18 animals for all groups 
except for female control group where n=17 and 200 JAU/kg and 2,000 JAU/kg groups where 
n=12. 
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Results for hematology are shown in Table 11. Treatment-related changes 
were not observed in the JCP-allergen extract treatment group compared with 
the each vehicle control group.  
 
Table 11. Hematological finding of rats following 14 days oral 
administration of JCP-allergen extract. 
 
Values are expressed as mean ± SD of 3 animals in each group.  
*: p<0.05, **: p<0.01 (significantly different from 0 JAU/kg).  
  
Chapter IV. LOCAL IRRITATION  
 73
Results for blood chemistry are shown in Table 12. Treatment-related 
changes were not observed in JCP treatment groups compared with the each 
vehicle control group.  
 
Table 12. Blood chemical finding of rats following 14 days oral 
administration of allergen extract of Japanese cedar pollen. 
 
Values are expressed as mean ± SD of 3 animals in each group.  
*: p<0.05 (significantly different from 0 JAU/kg). 
 
No gross abnormalities were detected for rats in any group by necropsy at 
the treatment period and recovery period (data not shown). 
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There were no treatment-related differences in organ weights between the 
vehicle control and 10,000 JAU/kg groups (Figure 20).  
 
 
Figure 20. Organ weights of rats following 26 weeks oral administration 
of JCP-allergen extract. 
Rats were orally administered 250, 1,250 and 6,250 JAU/head of JCP-allergen extract (JCP-1, 
JCP-2. JCP-3) or vehicle (0 JAU/head; Vehicle-1, Vehicle-2, Vehicle-3) daily for 14 days at 
each dosage volume. Values are expressed as mean±SD of 3 animals in each group.  
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Results for histopathology are shown in summarized Table (Table 13). 
Histopathology revealed no toxicological changes in the mucosa of GI tract of 
the animals from vehicle -3 and JCP-3 groups (Figure 21) although some 
changes in organs occurred sporadically. In kidney, the pyelectasis were 
observed in each one animal of vehicle-3 and JCP-3 group (Table 13). They 
were slight changes and it is known that such changes are observed occasionally 
in normal animals.  
 
Table 13. Histopathological findings of rats following 14days oral 
administration of JCP-allergen extract. 
Finding 
Dose 
Vehicle-3 
(0 JAU/site) 
JCP-3 
(6,250 JAU/site) 
Digestive system 
 Esophagus 0 0 
 Stomach 0 0 
 Duodenum 0 0 
 Jejunum 0 0 
 Ileum 0 0 
 Cecum 0 0 
 Colon 0 0 
 Rectum 0 0 
 Liver 0 0 
Urinary system 
 Kidney 0 0 
 Dilatation, pelvic cavity 1 1 
Endocrine system 
 Adrenal 0 0 
 
Three rats/group were administered 2.5 mL of 10,000 JAU/mL JCP-allergen extract (JCP-3; 
6,250 JAU/site) or vehicle (Vehicle-3; 0 JAU/site) orally for 14 days. 
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Figure 21. H&E staining of GI mucosa sections from rats following 14 
days oral administered of JCP-allergen extract. 
Three rats/group were administered 2.5 mL of 10,000 JAU/mL JCP-allergen extract (JCP-3; 
6,250 JAU/site) or vehicle (Vehicle-3; 0 JAU/site) orally for 14 days. The bars indicate 
200 μm. 
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3.3  Short Summary 
The present findings show neither irritation of the GI tract mucosa nor 
systemic toxicity in rats after oral treatment with a JCP-allergen extract. There 
were no treatment-related changes on the observation on necropsy in the GI tract 
and by histopathology of mucosal tissues of esophagus, stomach, duodenum, 
jejunum, ileum, cecum, colon and rectum. It suggested no local irritation of the 
GI mucosa occurred in healthy rats after 14 days repeated oral treatment with 
JCP-allergen extract.  
The doses used in the study were much higher in systemic exposure 
(~800-fold based on 60 kg of human body weight) compared to the doses used 
in clinical, suggesting that SLIT-swallow at clinical doses should not exert 
remarkable adverse effects in patients with JC pollinosis. 
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4  Summary 
Two studies on local irritation were conducted as safety assessment of 
standardized JCP-allergen extract currently developed for SLIT in JC pollinosis. 
Oral mucosa was examined in the rabbits as first-of-contact site for SLIT. 
Mucosa of GI tract was examined in the rats as the contact site after swallowing 
of allergen extract in SLIT.  
Regarding oral mucosa, no treatment-related changes was seen in 
macroscopic observation throughout the dosing period and by histopathology of 
oral mucosal tissues including tongue, buccal and mouth floor. It suggested no 
local irritation of the sublingual/buccal mucosa occurred in healthy rabbits after 
7 days repeated sublingual treatment with JCP-allergen extract drug product 
with 10-times longer application than for clinical use.  
Regarding GI tract mucosa, no treatment-related changes in observation of 
the GI tract on necropsy on last day in 14 days dosing period and by 
histopathology of mucosal tissues of GI tract including the esophagus, stomach, 
duodenum, jejunum, ileum, cecum, colon and rectum. The doses used in the 
studies were much higher in systemic exposure based on body weight 
(~800-fold, 60 kg as human body weight) and more than 3-fold (6,250 JAU in 
rats by po vs 2,000 JAU in human by sublingual administration) in local 
exposure compared with the doses used in clinical. Local exposure level in this 
study is considered to be sufficient high compared to clinical use because 
actually a part of 2,000 JAU reached to GI tract in human such as stomach after 
swallowing in SLIT resulting much higher safety margin than 3-fold.  
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These data suggest that SLIT-swallow at clinical doses should not exert 
remarkable adverse effects in patients with JC pollinosis although further study 
is required in JCP extract -sensitized animals to evaluate the local irritation that 
appeared during SLIT in patients with JC pollinosis. 
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Chapter V. SAFETY EVALUATION ON 
GENOTOXICITY OF ALLERGEN EXTRACT OF 
JAPANESE CEDAR POLLEN 
 
1  Introduction 
Safety evaluation on genotoxicity is important for the development of new 
drug to assess the risk of carcinogenicity. For the new drug application to 
authority, it is required to extensive evaluation of genotoxicity with several tests 
and scientific explanation on genotoxicological risk of developmental product 
based on the data obtained from in vitro and in vivo tests (PFSB/ELD 
Notification 0920 No. 2, dated September 20, 2012). The ICH harmonized 
guideline among Japan, Europe and US indicates the standard battery of 
genotoxicity (ICH S2(R1), dated 9 November 2011).  
The bacterial reverse gene mutation test (also referred to as Ames test) is 
test system for the assessment of mutagenicity with detection of relevant genetic 
changes and widely used for screening from the point of view of genotoxicity 
and carcinogenicity. The majority of genotoxic rodent and human carcinogens 
are detected by this test. In this test system, auxotrophic strains of bacteria are 
used which caused mutation in the genes involved in amino acid metabolism. It 
is possible to count the forming colonies in medium amino acid is insufficient 
when reverse mutation occurs. Potentials of chromosomal aberration and 
micronuclei induction could be evaluated in mammalian cells in vitro and in 
vivo  
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Regarding the extensive review following to the guideline, a series of 
genotoxicity study was conducted for the safety evaluation on genotoxicity of 
JCP; reverse mutation test in bacterial cells (Ames test), in vitro chromosomal 
aberration test and in vivo bone marrow micronucleus test (Table 14).  
 
Table 14. The battery of geontoxicity study of JCP-allergen extract.  
ICH guideline S2(R1) 
Option 1 
Categories of the 
mutagenicity tests Materials Test for JCP 
i.Test for gene mutation 
in bacteria (Ames test) Gene mutation Bacteria 
Reverse mutation test in 
bacterial cells (Ames 
test) 
ii.In vitro Cytogenetic 
test for chromosomal 
damage 
Chromosome 
aberration 
Mammalian 
cells  
In vitro chromosomal 
aberration test in 
Chinese hamster lung 
cells 
iii.In vivo test for 
genotoxicity 
Chromosomal 
damage using rodent
hematopoietic cells 
Animal 
In vivo bone marrow 
micronucleus test in 
rats 
 
 
All studies were conducted in accordance with the Guidelines for 
Genotoxicity Studies in compliance with the GLP Regulations specified by the 
Japanese Ordinance. 
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2  Materials and Methods 
2.1  Standardized allergen extract of Japanese cedar pollen 
Standardized JCP-allergen extract is glycerinated JCP extract obtained by 
managed process and controlled by the content of Cry j 1, a major allergen 
protein of Japanese cedar pollen (Yasueda et al., 1983), and its allergen potency 
is expressed as Japanese allergen unit (JAU) defined based on skin reaction 
(Yasueda et al., 1996). Standardized JCP-allergen extract original solution 
10,000 JAU/mL (10,000 JAU/mL JCP) is defined to contain 7.3-21 ug/mL of 
Cry j 1(Yasueda et al., 1996). Test liquids of 200 and 2,000 JAU/mL were 
formulated by dilution of 10,000 JAU/mL JCP to provide the indicated potency, 
respectively (Torii Pharmaceutical Co. Ltd., Tokyo, Japan).  
In genotocixity study (bacterial reverse mutation test; that is Ames test, in 
vitro chromosomal aberration test and in vivo micronucleus test), 10,000 
JAU/mL JCP and its diluted solutions were used. Doses of 12,500, 25,000 and 
50,000 JAU/kg were administered subcutaneously to rats in bone marrow 
micronucleus test. In addition, 50% glycerin-containing sodium chloride was 
used for the vehicle control group. 
 
2.2  Reverse mutation test in bacterial cells (Ames test) 
The mutagenic potential of JCP was evaluated in a bacterial reverse 
mutation test using four histamine auxotrophic strains of Salmonella 
typhimurium (S. typhimurium) TA98, TA100, TA1535 and TA1537 and one 
tryptophan auxotrophic strain of Escherichia coli (E. coli) WP2uvrA. The test 
solutions were prepared by dilution of 10,000 JAU/mL JCP, with 50% glycerin 
containing sodium chloride and treated using the pre-incubation method with or 
without metabolic activation with S9 mix (AroclorTM 1254-induced rat liver S9, 
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Oriental Yeast Co. Ltd., Japan). The dose was expressed as %concentration of 
test solution. Two plates per treatment were used in the dose-range finding test 
and main test. The plates were incubated at 37˚C for 48 hours and the revertant 
colonies were counted and examined. The results were judged positive if the 
mean number of revertant colonies showed a dose dependent increase that was 
two-fold greater than that of vehicle control at one or more concentrations.  
A dose-range finding test was performed on all of strains both with and 
without S9 mix at the following doses of 10,000 JAU/mL JCP. The 100% of 
10,000 JAU/mL was selected as the highest dose and lower dose levels, 25.0, 
6.25, 1.56, 0.391, 0.0977 and 0.0244% of JCP were set at a geometric ratio of 4. 
Distilled water was used as a negative control. The 50% glycerin solution 
containing sodium chloride was used as a vehicle control. Positive controls 
consisted of 0.01 g/plate of 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide (AF-2) 
for TA100 and WP2uvrA without S9 mix activation; 0.1 μg/plate of AF-2 for 
TA98 without S9 mix activation; 0.5 μg/plate of sodium-azide for TA1535 
without S9 mix activation; 80 μg/plate of 9-aminoacridine hydrochloride for 
TA1537 without S9 mix activation; 1, 2, 10, 0.5, and 2 μg/plate of 
2-aminoanthracene (2AA) for TA100, TA1535, WP2uvrA, TA98, and TA1537, 
respectively with S9 mix activation. 
 
2.3  In vitro Chromosomal aberration test in Chinese hamster lung cells 
The potential for JCP to induce chromosomal aberrations in cultured 
mammalian cells was evaluated using a fibroblast cell line from the lung of a 
Chinese hamster (CHL/IU; DS Pharma Biomedical, Osaka, Japan), either with 
or without S9 mix activation. The test solutions were prepared by dilution of 
standardized JCP-allergen extract original solution (10,000 JAU/mL) with 
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distilled water and treated with or without metabolic activation with S9 mix 
(Aroclor™ 1254-induced rat liver S9, Oriental Yeast). The dose was expressed 
as %concentration of test solution. 
For short-time treatments, the treatment time was 6 hours and viable cell 
counts and preparation of chromosome specimens were conducted 18 hours after 
completion of treatment. For continuous treatment, the treatment time was 24 
hours and viable cell counts and preparation of chromosome specimens were 
conducted at completion of treatment. Two dishes were used per dose, condition 
(with or without S9 mix activation) and exposure time. The positive control 
articles were diluted with culture media to dimethylnitrosamine (DMN; Wako 
Pure Chemical Industries, Osaka, Japan) set at a concentration of 500 g/mL for 
the 6 and 24-h treatments without S9 mix activation and with mitomycin C 
(MMC; Kyowa Hakko Kirin, Tokyo, Japan) at a concentration of 0.1 g/mL for 
the 6 and 24-h treatment without S9 mix activation. One hundred well-spread 
metaphases per dish were examined microscopically for structural and 
numerical chromosomal aberrations. The value of the incidence of cells with 
chromosomal aberrations was recorded according to the dish and the mean for 
each dose level was calculated. For each dose level, the mean incidences were 
evaluated as lower than 5%: negative, 5% or more but less than 10%: equivocal 
and 10% or more: positive, with no statistical comparisons being made.  
Based from a dose-range finding study (dose-levels: 12.5, 25, 50 and 
100% of vehicle; 50% glycerin containing sodium chloride), the dose level of 
the definitive test were selected as 6.25, 12.5 and 25% of the 10,000 JAU/mL 
JCP-allergen extract for the 6-h treatment with or without S9 mix activation and 
24-h treatment without S9 mix activation. Thus, the final doses of JCP-allergen 
extract in the definitive test were 625, 1,250 and 2,500 JAU/mL. 
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2.4  In vivo Bone marrow micronucleus test in rats 
An in vivo mammalian erythrocyte micronucleus test was conducted with 
approval of the Institutional Animal Care and Use Committee of Nihon 
Bioresearch Center, Japan in accordance with laboratory animal welfare 
guidelines.  
Male Crl:CD (Sprague-Dawley) rats (Charles River, Japan), aged 5 weeks, 
with body weights of 135–148 g for a preliminary dose-finding study and 123–
146 g for the definitive micronucleus study were housed in a 12-h light-dark 
cycle at a temperature of 21.7–24.5 ˚C, with ad libitum access to food (certified 
diet CRF-1, Oriental Yeast Co., Ltd.) and water. The 31 rats were stratified by 
body weight and randomly assigned to one of six groups (five rats/group) on the 
first day (day 1) prior to dosing. In the preliminary dose-finding study using 
doses of 12.5, 25, 50 and 100% JCP, no cytotoxicity was observed for all doses. 
The 100% dose was set as the highest dose, and doses of 50 and 25% were 
selected as middle and low doses, respectively. Animals were dosed twice 
subcutaneously with 5 mL/kg at 24 h-intervals. The doses of JCP-allergen 
extract were 12,500, 25,000 and 50,000 JAU/kg. A 50% glycerin solution 
containing sodium chloride and distilled water were administered 
subcutaneously as vehicle control and negative control, respectively. Mytomicin 
C (MMC, Kyowa Hakko Kirin) was used as a positive control and administered 
at a dose of 2 mg/kg/day by intraperitoneal administration.  
All animals were observed for clinical signs, mortality and body weights 
were measured prior to and after dosing on days 1 and 2, and just prior the 
preparation of specimens. All animals were euthanized by 20 v/v% isoflurane 
anesthesia exposure 24 h after the final dosing. The femur was excised for the 
preparation of bone marrow cell suspensions. Slides coated with acridine orange 
were prepared for incidence of micronucleated polychromatic erythrocyte 
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(%MNPCE) analysis among 2,000 polychromatic erythrocytes per animal. To 
assess bone marrow cell proliferation, the ratio of reticulocytes (%RET) in 1,000 
erythrocytes was analyzed using slides coated with new methylene blue for 
Giemsa staining.  
Statistical analyses were performed between the negative control group 
and vehicle control group, negative control group and positive control group, 
and between vehicle control group and test article treated groups. The 
conditional binomial test (Kastenbaum–Bowman test) was used to 
calculate %MNPCE and the Student’s t-test was to calculate %RET. 
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3  Results and Discussion 
3.1  Reverse mutation test in bacterial cells (Ames test) 
In the dose-finding test, inhibition of bacterial growth was observed on the 
plates at 100% of JCP for TA1537 without S9 mix. However no inhibition of 
bacterial growth inhibition was observed at any dose tested for TA98. TA100, 
TA1535, TA1537 and WP2uvrA with or without S9 mix and TA 1537 with S9 
mix. No precipitation of the test article was observed at the start or end of the 
treatment in all conditions. The test article did not increase the number of 
revertant colonies of any strain ≥ two-fold when compared with the vehicle 
control with or without S9 mix (data not shown). From these results, the 
definitive test was performed using the test solutions of 3.125, 6.25, 12.5, 25, 50 
and 100% of JCP-allergen extract on all strains without S9 mix.  
In the definitive test (Table 15), inhibition of bacterial growth was 
observed on the plates at 1,000 JAU/plate of JCP-allergen extract for TA1537 
without S9 mix. However, no inhibition of bacterial growth inhibition was 
observed at any dose tested for TA98, TA100, TA1535 and WP2uvrA with or 
without S9 mix and TA1537 with S9 mix. The test article did not increase the 
number of revertant colonies of any strain by ≥two-fold compared with the 
vehicle control with or without S9 mix (Table 2). No precipitation of the test 
article was observed either at the start or end of the treatments under all the 
conditions.  
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Table 15. Results of bacterial reverse mutation test (Ames test) 
conducted on JCP-allergen extract.  
Concentration 
(JAU/plate) 
Reverse colonies per plate (mean ± SD ) 
TA100  TA1535 WP2uvrA TA98  TA1537
-S9 +S9  -S9 +S9 -S9 +S9 -S9 +S9  -S9 +S9
Negative 
control  
(distilled water) 
138 142 
 
11 7 31 40 19 32 
 
14 19
0 151 143  11 8 32 32 18 35  10 20
31.25 NT 154  NT 9 NT 26 NT 34  7 18
62.5 147 154  12 7 29 41 21 26  11 16
125 131 144  8 8 37 37 19 29  8 17
250 166 149  10 7 31 36 18 31  11 20
500 139 162  10 8 22 29 19 38  12 17
1,000 156 NT  9 NT 36 NT 13 NT  10c NT
Positive  
controls a, b 538 1,068 
 
478 283 132 1,092 481 380 
 
401 191
 
NT: not tested 
a positive controls –S9: 0.01 µg/plate 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide (AF-2) for 
TA100 and WP2uvrA,  0.1 µg/plate AF-2 for TA98, 0.5 µg/plate sodium-azide for TA1535, 
80 µg/plate 9-aminoacridine hydrochloride for TA1537. 
b positive controls +S9: 0.5 1 and 10 µg/plate 2-aminoanthracene (2AA) for TA98, TA100 
and WP2uvrA , respectively. 2 µg/plate 2AA for TA1535 and TA1537. 
c Bacterial growth inhibition was observed. 
 
 
3.2  In vitro Chromosomal aberration test in Chinese hamster lung cells 
The dose-finding test of the chromosomal aberration test was conducted 
with vehicle (50% glycerin containing sodium chloride) at doses of 12.5, 25, 50 
and 100%. The incidence of cells with numerical chromosomal aberrations was 
less than 5% under all conditions. The 50 and 100% vehicle in the short treatment 
without S9 mix was equivocal and 100% of vehicle for continuous treatment was 
positive for the incidence of structural chromosomal aberrations of 5, 8 and 16%, 
respectively (data not shown). Cell viability was >90% with no cytotoxicity 
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under all conditions in the dose-finding test. No precipitation of the test article 
was observed at the start or end of treatments under all the conditions in the 
dose-finding test. 
In the definitive test, test solutions were 6.25, 12.5 and 25% of 
JCP-allergen extract, thus the final doses of treatment were 625, 1,250 and 2,500 
JAU/mL for the 6-h treatment with or without S9 mix and 24-h treatment without 
S9 mix. The incidence of cells with numerical and structural chromosomal 
aberrations was less than 5% in all JCP treatment group with short treatment or 
continuous treatment (Table 16). The negative control induced no chromosomal 
aberrations as expected. The positive control agents increased the percentage of 
cells with numerical or structural chromosomal aberrations. Thus, JCP-allergen 
extract was not considered clastogenic in this test system. No precipitation of the 
test article was observed at the start or end of the treatments in all the conditions. 
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Table 16. Results of in vitro mammalian chromosomal aberration test 
conducted on JCP-allergen extract.  
Concentration 
(JAU/mL) 
Numerical 
aberration 
 
Structural aberration 
Number 
of 
polyploid 
cells (%) 
 Types and numbers 
(cumulative) a 
Number of cells with 
chromosomal 
aberration (%) b 
 gap ctb csb cte cse frg +g -g 
Short-time treatment, 
-S9           
 Negative control 
 (distilled water) 1 (0.5)  0 0 0 1 0 0 1 (0.5) 1 (0.5) 
 625 2(1.0)  0 1 0 1 1 0 3 (1.5) 3 (1.5) 
 1,250 3 (1.5)  0 1 0 0 0 0 1 (0.5) 1 (0.5) 
 2,500 1 (0.5)  0 0 0 0 0 0 0 (0) 0 (0) 
 Positive control c 1 (0.5)  0 63 2 69 1 0 108 (54.0) 108 (54.0)
Short-time treatment, 
+S9           
 Negative control 
 (distilled water) 1 (0.5)  0 1 0 1 0 0 2 (1.0) 2 (1.0) 
 625 2 (1.0)  0 1 0 1 0 0 2 (1.0) 2 (1.0) 
 1,250 1 (0.5)  0 0 0 0 0 0 0 (0) 0 (0) 
 2,500 3 (1.5)  0 0 0 0 0 0 0 (0) 0 (0) 
 Positive control d 1 (0.5)  0 52 2 85 0 0 115 (57.5) 115 (57.5)
Continuous treatment           
 Negative control  
(distilled water) 1 (0.5)  0 2 0 0 0 0 2 (1.0) 2 (1.0) 
 625 0 (0)  0 0 0 0 0 0 0 (0) 0 (0) 
 1,250 2 (1.0)  0 0 0 0 0 0 0 (0) 0 (0) 
 2,500 2 (1.0)  0 0 0 1 0 0 1 (0.5) 1 (0.5) 
 Positive control e 0 (0)  0 45 2 36 0 0 81 (40.5) 81 (40.5) 
 
−S9, with metabolic activation; +S9, with metabolic activation; JAU, Japanese allergy units; 
a: ctb, chromatid break; csb, chromosome break; cte: chromatid exchange; cse: chromosome 
exchange; frg, fragmentation; b: (+g): total aberrant cells including the gap; (−g): total 
aberrant cells excluding the gap; c: 0.1 μg.mL mitomycin C; d: 500 μg/mL 
dimethylnitrosamine; e: 0.05 μg.mL mitomycin C. 
 
3.3  In vivo Bone marrow micronucleus test in rats 
In the in vivo micronucleus test, no mortality was observed following two 
administrations of JCP-allergen extract at 12,500, 25,000 or 50,000 JAU/kg. No 
clinical signs or change in body weight was observed when compared with the 
vehicle control group. The incidence of MNPCE and ratio of RET are shown in 
Table 17.  
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The %MNPCE in the JCP treatment group showed no significant 
difference compared with the vehicle control group and no dose-dependent 
change. No significant difference was observed for %RET compared with the 
vehicle control group. Administration of the positive control significantly 
increased the incidence of micronucleated cells as MNPCE and resulted in a 
significant decrease in the ratio of immature erythrocytes as RET compared with 
the negative control group. There was no possibility of the vehicle having an 
effect on the test system because there was no significant difference in the 
incidence of MNPCE and %RET compared with the negative control. Thus, it 
was concluded that JCP-allergen extract did not induce micronuclei in PCE of 
bone marrow of rats treated with up to 50,000 JAU/kg by subcutaneous 
administration. 
 
Table 17. Results of in vivo mammalian erythrocyte micronucleus test 
in rats administered with JCP-allergen extract. 
Dosage (JAU/kg) %MNPCE %RET 
Negative control 
 (distilled water) 0.09 ± 0.04 76.7 ± 0.54 
0 0.08 ± 0.03 76.1 ± 0.84 
12,500 0.12 ± 0.07 76.3 ± 0.97 
25,000 0.13 ± 0.04 76.8 ± 0.95 
50,000 0.07 ± 0.06 76.7 ± 2.30 
Positive control  
(2 mg/kg mitomycin C) 3.40 ± 0.34
** 66.3 ± 3.02## 
 
Animals were dosed twice with JCP-allergen extract and negative control at a 24h-interval 
subcutaneously.  
Positive control was dosed by intraperitoneal administration. 
Values are expressed as mean ± SD of 5 animals in each group. 
**: p<0.01 (significantly different from negative control).  
##: p<0.01 (significantly different from negative control). 
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Regarding the safety margin, highest dose of this study, 50,000 
JAU/kg/day, corresponds to approximately 1,500-times higher than the intended 
clinical dose level (2,000 JAU/man/day by sublingual administration) based on 
body weight. Thus, it is suggested that the JCP does not pose the potential to 
induce micronuclei for clinical use. This is supported by the absence of any 
adverse genotoxic or carcinogenic effects during over 15 years of clinical 
experience with SCIT products with Japanese cedar pollen allergen extracts. 
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4  Summary 
The safety evaluation on genotoxicity of JCP was conducted by a series of 
two in vitro tests and one in vivo test. The in vitro tests were reverse mutation 
test in bacterial cells (Ames test) to assess the mutagenic properties and 
mammalian chromosomal aberration test in Chinese hamster lung cells to 
evaluate the potential for induction structural or numerical chromosome 
aberrations. The in vivo test was mammalian erythrocyte micronucleus test in 
rats to determine the potential to induce micronuclei.  
The Ames test detected no cytotoxic effects except for TA1537 at 100% 
JCP without S9 mix, or mutagenic effect. The chromosomal aberration test was 
conducted at highest concentration of 25%JCP as non-effective dose for the test 
system, and showed that JCP induced no numerical or structural aberrations and 
was not clastogenic. In addition, the in vivo micronucleus test showed no 
increase in micronuclei frequency in polychromatic erythrocytes. Regarding the 
safety margin of in vivo micronucleus test, highest dose of this study, 50,000 
JAU/kg/day, corresponds to approximately 1,500-times higher than the intended 
clinical dose level (2,000 JAU/man/day by sublingual administration) based on 
body weight.  
In this study, I presented that the genotoxicity potential in clinical use is 
considered to be very low. This is supported by the absence of any adverse 
genotoxic or carcinogenic effects during over 15 years of clinical experience of 
Japanese cedar pollen allergen extracts as SCIT products. 
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Chapter VI. CONCLUSION AND PERSPECTIVE 
Prevalence of JC pollinosis have been increasing (Kaneko et al, 2004; 
Okubo et al., 2011; Yamada et al., 2014) and it is considered to be a national 
affliction (Kaneko et al., 2005; Yamada et al., 2014) in Japan. Generally in 
allergic disease, the first approach to deal with is avoidance of antigens/allergen 
such as pets (eg. dogs and cats) and some foods if it is possible. It is difficult to 
completely eliminate antigens/allergen such as house dust mite and pollen 
though they could be reduced by cleaning and dehumidification for house dust 
mite and taking a mask and glasses is effective for pollen. Several type of 
treatment are recommended against allergic rhinitis in the Japanese Guideline 
for allergic rhinitis (Okubo et al., 2011); pharmacotherapy (chemical mediator 
receptor antagonist such as anti-histamine, mast cell stabilizer, steroids, 
autonomic drugs and others), operative treatment and AIT including SCIT and 
SLIT. Recently, SLIT has much attention and considered to be a safe and 
efficient treatment as being possible to cure allergic disease although 
symptomatic treatment by pharmacotherapy allows tentative relief from 
symptoms (Bousquet et al., 1998; Didier et al., 2011; Nelson et al., 2011; Cox et 
al., 2012; Durham et al., 2012).  
Here, safety was evaluated for the development of a drug for SLIT with 
standardized JCP-allergen extract (Sublingual droplet of JCP). The JCP-allergen 
extract exhibited safe profile in long-term repeated toxicity study, local irritation 
study (oral area, GI tract) and in vitro and in vivo genotoxicity studies, 
suggesting it is suitable for SLIT. 
 
In Chapter I, introduction and background information was noted 
regarding JC pollinosis caused by JCP, allergen extract of JCP, AIT including 
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SCIT and SLIT, standardization of allergen extract for AIT, background of 
development of Sublingual droplet of JCP. In Chapter II, the biological profile 
of JCP-allergen extract was discussed. Levels of the JCP specific-antibody in 
serum was significantly increased following i.p. administration with alum 
compared with naïve serum, showing immunogenicity of JCP-allergen extract. 
Allergic specific immune reaction was confirmed by PCA reaction in rats, 
indicating allergen profile of JCP-allergen extract. These are basic information 
of biological profile showed by JCP-allergen extract which is considered to 
modulate immunoreactions known in the mechanism of AIT. In addition, it is 
very interesting that there was the difference of reactivity of JCP-allergen 
extract in saliva and gastric juice in in vitro assay. The activity of major 
allergens (Cry j 1 and Cry j 2) was detected in human saliva although 
disappeared immediately in gastric juice. It suggests that major allergens in JCP 
are stable in the mouth of JC pollinosis patients, and immediately 
metabolized/degraded following been swallowed and reached to stomach. The 
missing activity of proteins in gastric juice is considered to be consistent with 
less incidence of systemic adverse effect seen in SLIT-swallow. 
In Chapter III, no JCP-allergen extract related toxicologically changes 
were shown in long-time repeated administration of JCP-allergen extract in rats. 
NOAEL was greater than 10,000 JAU/kg/day for systemic toxicity, equivalent 
to 300-fold the human dose. In Chapter IV, the JCP-allergen extract induced no 
local irritative response in oral mucosa as well as mucosa of GI tract in rabbit 
and rats respectively, suggesting that SLIT-swallow at clinical doses should not 
exert remarkable adverse effects in patients with JC pollinosis. These 
toxicological studies were conducted using normal animals because the purpose 
of these studies was to assess the physical properties of the drug. Further study 
is required in JCP extract -sensitized animals to evaluate the toxicity that 
appeared during SLIT in patients with JC pollinosis. In Chapter V, it was 
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demonstrated to be no potential in genotoxicity of the JCP-allergen extract and 
1,500-fold of safety margin. 
 
Okamoto et al. demonstrated improvement of the nasal and ocular 
symptoms of JC pollinosis by clinical trial with standardized JCP-allergen 
extract (manuscript in preparation). Based on present nonclinical studies, the 
safety profile supports the safe use of standardized JCP-allergen extract for 
SLIT in JC pollinosis patients.  
On the other hand, the mechanism of SLIT is not understood entirely. The 
changes on immunoglobulin-based immunological reaction (IgG subtype, IgE, 
IgA in SLIT) and cell-based immune response induced by repeated 
administration of allergen extract are key events in mechanism of AIT and need 
to be analyzed. 
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